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ABSTRACT 
Collaborative TB/HIV management is essential to prevent and treat TB among 
HIV-positive TB patients, and to ensure that HIV-positive TB patients are 
detected and treated appropriately. 
    
This quantitative, descriptive, contextual study identified problems encountered 
during the implementation of TB case detection among HIV-positive individuals in 
one Ethiopian hospital. During December 2012, 300 checklists were completed 
about HIV-positive patients’ TB/HIV collaborative management, as reflected in 
their files.   
 
Only 60.2% of HIV-positive patients, who should have received Isoniazid 
preventive treatment (IPT), were placed on this treatment. X-rays and laboratory 
examinations of sputum samples were not done according to the Ethiopian 
guidelines. Most TB patients’ initial screening was done by nurses, not doctors, 
and included only symptom screening without CD4 count considerations. 
 
Managers and healthcare personnel should improve IPT, especially for those 
with early HIV infection and timely effective treatment for those suffering from TB, 
before complications arise.  
 
Keywords: Isoniazid preventive treatment (IPT), TB case detection, TB/HIV 
collaborative management, TB and HIV in Ethiopia 
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 1 
CHAPTER 1 
 
INTRODUCTION AND BACKGROUND INFORMATION 
 
1.1          INTRODUCTION 
 
Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium 
Tuberculosis (MTB), an acid-fast bacillus (AFB), which is rod-shaped (WHO 
2011:3).  Transmission of this infection occurs through the airborne spread of 
droplets containing bacilli expelled by infected persons’ coughing and sneezing, 
which are then inhaled by other persons. In general, a relatively small proportion 
of people infected with MTB will develop the TB disease. However, the 
probability of developing TB is much higher among people infected with the 
human immunodeficiency virus (HIV) (WHO 2011:3). In 2010, there were 8.8 
million incident cases of TB globally, 1.1 million deaths from TB among HIV-
negative people, and an additional 0.35 million deaths from HIV-associated TB. 
During the same year, there were 5.7 million notifications of new and recurrent 
cases of TB, equivalent to 65% of the estimated number of incident cases in 
2010. India and China accounted for 40% of the world’s notified cases of TB in 
2010, Africa for a further 24%, and there were 22 high-TB burden countries 
(HBCs), accounting for 82% of TB cases, according to estimates from the World 
Health Organization (WHO 2011:10). 
 
According to the WHO (2011:3), despite the decades-long availability of highly 
effective anti-TB treatment, TB remains a major global health problem. In 1993, 
the WHO declared TB a global public health emergency, at a time when an 
estimated 7–8 million TB cases and 1.3–1.6 million TB deaths were occurring 
each year.  In 2010, there were an estimated 8.5–9.2 million cases and 1.2–1.5 
million deaths (including deaths from TB among HIV-positive people), according 
to the WHO (2011:3). TB is the world’s second deadliest infectious disease, after 
HIV, which for its part caused an estimated 1.8 million deaths in 2008. However, 
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if TB is detected early and treated effectively, people with TB can become non-
infectious within 72 hours and can be effectively cured after six months’ 
treatment. Today, multidrug-resistant TB (MDR-TB) and extensively drug-
resistant TB (XDR-TB), HIV-associated TB, and weak healthcare systems pose 
major challenges for the effective implementation of TB control programmes 
(FMoH 2008b:3; WHO 2008a:1-5; WHO 2007d:23-24; WHO 2011:3, 4).  
 
According to the WHO (2011:10), about 13% of TB cases occur among people 
living with HIV. TB is strongly associated with HIV, because HIV leads to 
progressive immune deficiency and increased susceptibility to infections, 
including TB.  The WHO (2007a:36) has stated that HIV increases susceptibility 
to infection with MTB, and that HIV also increases the risk of MTB’s rapid 
progression. This risk increases with progressive immune suppression. HIV not 
only increases the risk but also the rate of progression of recent or latent MTB 
infections into the TB disease. The annual risk of developing TB, amongst people 
living with HIV (PLWHIV) for those co-infected with MTB, has reached 50.0%, as 
compared to a 5-10.0% life-time risk for HIV-negative individuals. HIV also 
increases the likelihood of TB re-infections and relapses (WHO 2007a:38).  
 
According to the WHO (2011:29) a definite case of TB is defined as a patient with 
MTB identified from a clinical sputum specimen, either by culture, or by a newer 
method such as molecular line probe assay. In countries that lack the laboratory 
capacity needed to routinely identify MTB, a pulmonary case with one or more 
initial AFB positive sputum specimens is also considered to be a “definite” case, 
provided that there is functional external quality assurance, including the blind re-
checking of laboratory results. 
 
According to WHO (2007b:38) , the prevalence and mortality of all forms of TB 
(pulmonary and extra-pulmonary TB combined) is estimated to be 546 and 73 
per 100 000 of the population respectively.  
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1.2          BACKGROUND INFORMATION 
 
The African region has the world’s highest TB incidence rate per capita of 363 
per 100 000 persons (WHO 2008a:1). According to the Ethiopian Federal 
Ministry of Health (FMoH: 2008b:3), Ethiopia stands at seventh place in a global 
ranking by estimated number of pulmonary TB (PTB) cases, and during the years 
2006 and 2007, Ethiopia registered a total of 129 743 cases of TB. The 
estimated incidence of TB in Ethiopia is 152 and 341 per 100 000 persons for 
new smear positive pulmonary and all forms of TB respectively. TB has been 
recognised as a major public health problem since the 1950s and remains a 
major public health problem in many countries, including Ethiopia. After the 
introduction of a National TB Control Programme (NTP) by the WHO, Ethiopia 
adopted, and subsequently instituted, the National TB Control Programme in 
1976 (FMoH 2005:1). Since then, the rate of TB case detection has increased, 
treatment and immunisations have been scaled up, and the disease pattern has 
started to decline in this country. As part of a global movement to eradicate TB, 
the possibility of eradicating TB also appeared to be on the horizon in Ethiopia.  
 
Since Ethiopia detected two cases of Acquired Immune Deficiency Syndrome 
(AIDS) in 1984, the HIV and TB epidemics in the country have grown rapidly. The 
HIV epidemic started to fuel TB, and TB continues to be one of the top causes of 
mortality in Ethiopia (FMoH 2008a:12).  According to the FMoH (2012:43), 
approximately 41% of newly identified HIV-positive TB cases received treatment 
for both TB and HIV in 2009 and 2010. Routinely collected health facility data 
from 2010 indicate that 43% of notified TB patients were tested for HIV, and 15% 
had HIV co-infection. Among the identified HIV positive TB patients, 69% were 
given co-trimoxazole prophylactic (CPT) therapy, while 39% were given highly 
active anti-retroviral therapy (HAART). In addition, 44% of HIV-positive patients 
were screened for TB, and 6.6% of HIV-positive patients were provided with 
isoniazid prophylactic therapy (IPT). 
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The main objectives of TB case detection are to cut the chain of transmission 
and to start earlier and more effective treatment (FMoH 2008b:25). All suspected 
cases of any form of TB must be examined according to standardised diagnostic 
procedures, of which the microscopic examination of sputum is the most 
important and reliable. By rank of importance the diagnostic methods used to 
confirm or exclude TB are microscopic examination of sputum smears, 
radiological investigation, acid-fast bacillus (AFB) culture, and histo-pathology, all 
of which are available in Ethiopia (FMoH 2008b:25). 
 
No part of the world has been spared from the HIV/AIDS epidemic. In Ethiopia 
the adult prevalence of HIV was estimated to be 2.2% in 2008; the prevalence 
rates among the urban and rural populations were estimated at 7.7% and 0.9% 
respectively (FMoH & FHAPCO 2007b:6). The total number of PLWHIV in the 
same period was estimated to be 1 037 267 adults and 68 136 children. The 
estimated number of PLWHIV in Ethiopia in need of ART in 2008 was 289 734 
adults and 17 274 children under the age of 14 (FMoH & FHAPCO 2007c:6). 
 
Based on lessons learned from the promotion of the HIV testing (ProTEST) 
model, a WHO project piloted and used voluntary counselling and testing (VCT) 
as an entry point in three countries of sub Saharan Africa (SSA) with a high HIV 
prevalence and TB burden.  The WHO subsequently appealed to four SSA 
countries, including Ethiopia, with a high HIV prevalence and TB burden to 
introduce and implement TB/HIV co-management programmes by the end of 
2001 (FMoH & FHAPCO 2007c:13). The FMoH expressed its commitment to the 
WHO’s call, and co-ordinated the establishment of a TB/HIV advisory committee 
in 2002. The TB/HIV implementation programme in Ethiopia was then piloted at 
nine sites which served as testing grounds for the development of training 
materials, recording and reporting formats, referral systems, and TB/HIV 
implementation guidelines. During August 2007, TB/HIV collaborative activities 
were implemented in 138 hospitals and 280 health centres and private clinics 
providing ART services throughout Ethiopia (FMoH & FHAPCO 2007c:12). 
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According to the FMoH and FHAPCO (2007b:1), one hospital in the Oromiya 
region was one of the pilot sites for the implementation of the TB/HIV 
collaborative activities in Ethiopia (FMoH 2006:12). According to this hospital’s 
data, this HIV clinic attends to an average of five new PLWHIV and 150 follow up 
PLWHIV each day,  totalling 155 patients per day. In this study, the researcher 
will assess TB case detections among PLWHIV at this hospital by reviewing the 
records of HIV patients who had been diagnosed at least six months prior to the 
date of data collection.  
 
The main objective of the WHO and the FMoH TB/HIV Guidelines are to 
establish a co-ordinating mechanism for TB and HIV programmes and to 
increase the detection of TB among PLWHIV and the vice versa (WHO 2008a:1; 
FMoH & FHAPCO 2007c:9).  
 
According to the WHO (2008a:1) and the FMoH and FHAPCO (2007c:10), the 
guidelines for collaborative TB/HIV management include the following twelve 
activities: 
• Setting up a coordinating body for TB/HIV activities effective at all levels 
• Carrying out joint TB/HIV planning 
• Conducting monitoring and evaluating processes 
• Establishing intensified TB case-finding 
• Ensuring TB infection control in healthcare and congregate settings 
• Conducting surveillance of HIV prevalence among TB patients 
• Introducing Isoniazid Preventive Therapy (IPT) for all PLWHIV 
• Providing HIV testing and counselling to all TB patients 
• Introducing HIV prevention methods 
• Introducing co-trimoxazole preventive therapy (CPT) for all PLWHIV  
• Ensuring HIV/AIDS care and support  
• Introducing ART when the patient is eligible for treatment 
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According to the Ethiopian TB/HIV Guidelines (FMoH & FHAPCO 2007b:23), an 
HIV-positive patient is eligible to start IPT after excluding active TB (requiring 
effective TB treatment). Regular screening for TB among HIV-positive patients, at 
every stage of the disease, is one of the key TB/HIV collaborative activities 
(FMoH 2008a:25), with the aim of reducing the burden of TB in PLWHIV. 
Screening for TB is conducted at HIV clinics. Based on the result of this 
screening, patients will start TB prophylaxis with Isoniazid (INH) if the screening 
result is negative, or will be referred to a TB clinic for effective treatment of TB if 
the HIV patient is diagnosed as suffering from TB. 
 
 
1.3          RESEARCH PROBLEM 
According to the WHO (2011:28), between 1995 and 2010, 55 million TB patients 
were treated in TB national programmes that had adopted the DOTS/Stop TB 
Strategy; 46 million (83.6%) of these people were successfully treated. These 
treatments saved an estimated 6.8 million lives compared with the pre-DOTS 
standard of care. In 2010, 34% of notified TB patients knew their own HIV status.  
The highest rates of HIV co-infection in TB patients are in the African Region, 
where 44% of TB patients, who had used VCT services, were HIV-positive in 
2010.  The global coverage of ART for TB patients living with HIV remains low 
(only 46%), despite the large increase in HIV testing among TB patients, and the 
WHO recommendation that ART should be provided to all TB patients living with 
HIV regardless, of their CD4 cell count (WHO 2011:59).  
Ethiopia is one of the worst affected countries by the TB/HIV co-epidemic. The 
WHO Global Report 2008 estimated that in Ethiopia 40% of TB patients tested 
for HIV were HIV-positive, while routine data from health facilities indicated that 
31% of TB patients were HIV-positive (FMoH 2008a:73).  No obvious explanation 
could be found from available reports to explain this apparent discrepancy in 
estimates of HIV prevalence among TB patients. 
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According to the FMoH (2008:3), Ethiopia has reached a 36% rate of TB case 
detection and an 85% rate of treatment outcome targets. The WHO’s standards 
require 70% case detection and 85% treatment outcome rates. Ethiopia has 
adequate treatment outcomes for TB patients, but the rate of case detection 
remains below the WHO standard (FMoH 2008b:1, 4; WHO 2011:13, 28). 
This study’s research problem could thus be summarised as: Ethiopia’s TB/HIV 
collaboration guidelines specify that HIV-positive patients should be screened for 
TB. It is unknown to what extent this activity is implemented and, if implemented,  
the outcomes of such screening activities are unknown. Consequently, this study 
will investigate HIV patients’ referrals for TB screening and subsequent TB 
diagnoses and treatment at one hospital in Ethiopia. 
 
1.4          RESEARCH QUESTIONS 
The researcher posed the following research questions:  
• What problems are encountered during the implementation of the TB/HIV 
guidelines at one hospital in Ethiopia? 
• Are TB case detections among HIV-positive persons conducted according 
to the TB/HIV co-management guidelines? 
• What diagnostic procedures are used to detect TB among HIV-positive 
persons? 
• How long after being diagnosed as HIV-positive was a patient referred for 
TB investigations? 
1.5          PURPOSE OF THE STUDY 
 
The purpose of this study was to identify the procedures followed to implement 
TB case detection among HIV-positive persons at one hospital in Ethiopia. The 
time and type of TB diagnostic procedures were examined, as well as the 
prescribed anti-TB treatment. Based on the findings of this study, 
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recommendations might be provided for the improvement of existing TB/HIV 
management guidelines.  In addition, the findings might be of value for improving 
TB diagnosis amongst HIV-positive persons, and for increasing the number of  
 
HIV-positive patients referred for effective TB treatment at the participating 
hospital. 
 
1.6          RESEARCH OBJECTIVES 
 
Specific objectives of this study were to:  
 
• Identify problems encountered during the implementation of the TB/HIV 
guidelines at one hospital in Ethiopia 
• Assess whether TB case detections among  HIV-positive persons are 
conducted according to the TB/HIV management guidelines 
• Identify what diagnostic procedures have been used to detect TB among 
HIV-positive persons  
• Identify how long after being diagnosed as HIV-positive a patient was 
referred for TB investigations. 
1.7           ASSUMPTIONS UNDERLYING THE STUDY 
 
According to Shields and Tajalli (2006), conceptual frameworks include working 
hypotheses, descriptive categories, practical ideal types, models of operations 
research, and formal hypotheses. The objectives of this study and the TB/HIV 
guidelines provided by the WHO and FMoH formed the basis for the conceptual 
framework and assumptions underlying this study.  
 
This framework guided the research process. For adequate TB case detection, it 
is reasonably assumed that all PLWHIV registered at a specific HIV clinic must 
receive TB screening, proper recording, and follow-up treatment and 
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consultations.  These assumptions framework were adopted for the logical 
organisation of data collection during this study’s review of the patients’ records. 
 
1.8           SIGNIFICANCE OF THE STUDY 
 
This study was deemed to be valuable for the following reasons:  
 
• This study might contribute to the existing body of knowledge related to 
TB diagnosis of HIV-positive persons at one hospital in Ethiopia, as well 
as about the referral of HIV patients for TB screening, diagnosis and 
treatment.  
• It could also provide information about the outcomes of INH prophylaxis 
and TB treatment for specific HIV-positive persons  
• Recommendations could be made, based on the research findings, that 
might contribute to the enhancement of TB case detection among HIV-
positive persons, as well as the improvement of TB/HIV collaborative 
services provided at one hospital in Ethiopia.   
• Ultimately, TB treatment and INH outcomes amongst HIV-positive persons 
could be improved with benefits for the patients concerned and 
considerable savings for Ethiopia’s healthcare services. 
 
1.9           RESEARCH METHODOLOGY 
 
This study adopted a quantitative, descriptive, and contextual research design in 
so far as the researcher was interested in analysing quantifiable data available 
from the HIV positive patients’ files.  
 
1.9.1     Study design 
 
This study was descriptive in nature because the researcher observed a situation 
(the referral of HIV-positive persons for TB screening) and then described what  
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had been observed (Donald et al 2010:27).  The description of the phenomenon 
covered TB diagnosis among HIV-positive patients in one hospital in Ethiopia. 
This study was a formal, objective, systematic quantification used to describe a 
situation (Burns & Grove 2005:44), comprising reviews of records of registered 
HIV-positive patients to identify whether their TB screening had been conducted 
in accordance with Ethiopia’s TB/HIV collaborative guidelines. Statistics were 
used to summarise and describe the data. 
 
1.9.2     Research setting 
 
The researcher conducted the study at one of the nine Ethiopian public health 
facilities where TB/HIV collaborative management has been piloted since 2005.  
The patients who received TB/HIV co-management services at this hospital 
came from diverse backgrounds in terms of race, religion, gender, education, 
geography, and income.   
 
1.9.3     Research population 
 
A research population is the full data set on which the researcher focuses. The 
site population for this study would comprise all hospitals and all clinics providing 
services to HIV-positive patients in Ethiopia. 
 
1.9.4 Sample and sampling technique 
 
Sampling is the process of selecting a portion of the population to represent the 
entire population and a sampling design refers to decisions concerning whether 
probability (random) or non-probability (non-random) sampling will be done (Polit 
& Beck 2004:291). 
 
According to Polit and Beck (2004:292), probability sampling is more respected 
because of the greater veracity placed on the representativeness of probability 
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samples. Probability sampling constitutes a random selection of elements from a 
population. Random sampling involves a selection process in which each 
element in the population has an equal, independent chance of being selected 
(Polit & Beck 2004:295). In this study, simple random sampling was used to 
select the records of HIV positive persons visiting the participating clinic during 
the month of data collection.    
 
Simple random sampling was implemented on a daily basis.  The numbers of all 
files, belonging to patients who visited the clinic on a specific date, were written 
on slips of paper and placed into a container.  An independent individual was 
asked to draw 15 numbers blindly from this container.  These 15 files were 
acquired and checked. If any patient was younger than 18, or had been 
diagnosed as being HIV-positive less than six months prior to the date of data 
collection, these files were excluded from the sample and additional numbers 
were drawn blindly from the container until 15 files had been selected for every 
day. 
 
Only one HIV clinic at one hospital in Adama, Ethiopia, participated in this study.  
This clinic has been offering TB/HIV collaborative services since 2002 and was 
intentionally selected as it offers services to about 3 000 follow-up and 100 new 
PLWHIV per month, and it has been implementing TB/HIV collaborative services 
for ten years. 
 
A sample size of 300 patients’ files was used, equivalent to 10% of the estimated 
3 000 follow-up HIV patients who visit this clinic on a monthly basis. 
 
1.9.5       Data collection instrument 
 
A pre-tested checklist was used as a research instrument to collect information. 
The checklist had three sections. The first section was biographic. The second 
section collected information about TB screening and diagnosis. The third section 
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investigated whether HIV patients had been properly screened, diagnosed, and 
treated for TB at the HIV clinic.   
 
The validity and reliability of this study’s checklist will be discussed in chapter 3 
of this dissertation.   
 
1.9.6       Data collection 
 
Record reviews were the primary data sources for this study. The researcher 
numerically assigned a number to each checklist (ranging from 001 to 300) 
before commencing data collection.  The researcher kept a list indicating the 
checklist number and the corresponding patient’s HIV file number in an Excel 
sheet.  Only the researcher had access to this list, the hard copy was kept  
locked-up, and the MS Excel version was protected by a secure password on a 
computer to which only the researcher and the statistician had access.  After 
their numerical assignment, the following information was transcribed from the 
HIV registers onto the checklists:  
 
• Demographic profiles: age, gender, educational status, address of the 
patient, and marital status.    
• Was the HIV-positive patient screened for TB? 
• Was the HIV-positive patient referred from the HIV clinic to the TB clinic 
for treatment? 
• When was the first TB screening conducted? 
• What tests were used for TB screening? 
• Which category of healthcare professional performed the TB screening? 
• Which category of healthcare professional made a TB or non-TB 
diagnosis? 
• Was the patient eligible for TB treatment?   
• Was he/she treated for TB? 
• What was the outcome of the TB treatment? 
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• Did the patient receive INH prophylaxis? 
• If INH prophylaxis was administered, what was the outcome? 
 
1.9.7 Data analysis 
 
The data collected in this study were analysed using the Statistical Package for 
the Social Sciences (SPSS) version 17. The analysis comprises descriptive 
statistics such as frequency tables and graphs, chi-squares, p-values, and 
correlations (Pearson rho) to summarise and describe the data. The researcher 
entered the data into SPSS version 17 and a statistician checked the data entries 
from the completed checklists and assisted the researcher in calculating and 
interpreting the relevant statistics. 
 
1.10      ETHICAL CONSIDERATIONS 
 
According to David (2010:12), ethics provide guidelines for fair treatment of 
people participating in research. This quantitative study used self-designed 
checklists, completed by the researcher, to record from the patients’ files. A list of 
each patient’s file, and his/her correlated respondent number, have been kept 
under lock and key by the researcher in case the healthcare service or 
participating hospital authorities might wish to recheck the study’s findings.  No 
patient’s name and no healthcare worker’s name has been mentioned. In 
addition, neither the participating HIV clinic’s name, nor the hospital’s name, 
were mentioned in any report to avoid ethical issues.  
 
After completion of the research, the researcher will provide recommendations 
based on his research findings to the hospital studied.  Subsequent to the 
acceptance of the research report, all information recorded on hard copies and 
electronically will be destroyed by the researcher. 
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1.10.1     Anonymity and confidentiality  
 
No names were provided on the completed checklists, but each checklist had a 
specific respondent number (001-300). The researcher kept a separate list 
indicating the patient’s file number opposite the respondent number, in case any 
audit of the recorded data might be required by the healthcare authorities or by 
the examiners of this dissertation.   
 
Only the researcher had access to this list which was kept under lock and key 
and would be destroyed after the acceptance of this research report. The MS 
Excel list was protected by a secure password on a computer to which the 
researcher had sole access.  This list would be deleted (and again deleted from 
the ‘deleted items’ section of the computer) as soon as the hard copy had been 
printed and locked up.  The participating hospital’s name was not mentioned in 
any report. 
 
1.10.2     Ethical approval 
 
The research proposal was submitted to the Higher Degrees Committee of the 
Department of Health Studies, University of South Africa (Unisa), and obtained 
ethical approval. Thereafter, permission was received from the management of 
the participating hospital and Provincial Ministry of Health administration where 
the study was conducted (please see Annexure C). 
 
1.11         SCOPE AND LIMITATIONS OF THE STUDY 
 
The participating hospital  is situated in an urban area, in Adama, about 100 km 
from Addis Ababa, the capital city of Ethiopia. As a result, problems with out-of-
stock supplies, such as medicines, might be minimal compared to other hospitals 
and clinics in Ethiopia.  
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Only hospital records were used to produce information about the TB diagnosis 
of HIV-positive persons.  However, these records might not reflect all of the 
actual screening, diagnostic, treatment, and referral procedures.  For the purpose 
of this study, treatment not recorded was considered as treatment not 
administered. Only the recorded aspects could be examined and this depended 
on the completeness of the hospital’s records.  Incomplete records might have 
impacted on the reliability of the findings. 
 
Interviewing healthcare service providers and HIV-positive patients might have 
revealed different results, but interviews could not be conducted within the limited 
time and financial constraints applicable to this dissertation. (During the study the 
researcher was transferred to another country and could thus not conduct 
interviews). 
 
1.12          DEFINITIONS OF KEY CONCEPTS 
 
The following terms have been used throughout this dissertation and their 
meanings are defined in order that the researcher and readers could share the 
same understanding of these concepts.  
 
 A Pulmonary TB case refers to a patient with TB disease involving the lung 
parenchyma (WHO 2011:29). 
 
A TB case implies a definite case of TB is one in which a healthcare worker has 
diagnosed TB according to the NTG and treated the patient with a full course of 
TB treatment (WHO 2011:29). 
 
New TB case is a patient who has never had treatment for TB or who has taken 
anti-TB drugs for less than one month (WHO 2011:29). 
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A smear-negative pulmonary TB case implies that a patient with PTB does not 
meet the criteria for smear-positive TB. Diagnostic criteria should include at least 
two sputum smear examinations negative for AFB, radiographic abnormalities 
consistent with active pulmonary TB, no response to a course of broad-spectrum 
antibiotics (except in a patient for whom there is laboratory confirmation or strong 
clinical evidence of HIV infection), and a decision by a clinician to treat a patient 
with a full course of anti-TB chemotherapy. A patient with a positive culture, but a 
negative AFB sputum examination, is also a smear-negative case of PTB (WHO 
2011:29). 
 
A smear-positive pulmonary TB case refers to a patient who has one or more 
initial sputum smear examinations (direct smear microscopy) AFB-positive; or 
one sputum examination AFB-positive and radiographic abnormalities consistent 
with active pulmonary TB as determined by a clinician. Smear-positive cases are 
the most infectious, and thus of the highest priority, from a public health 
perspective (WHO 2011:29). 
 
1.13        LIST OF ABBREVIATIONS 
 
AFB  Acid-Fast Bacillus 
AIDS  Acquired Immune Deficiency Syndrome 
ART  Anti-retroviral therapy 
CD4             Cluster of Differentiation 4 
CPT             Co trimoxazole Prophylaxis Therapy 
DOTs  Directly Observed Treatment – Short Course 
EPTB  Extra-pulmonary Tuberculosis 
FHAPCO    Federal HIV/AIDS Prevention and Control Programme 
FMoH    Federal Ministry of Health  
HAART Highly Active Anti-retroviral Therapy  
HIV  Human Immunodeficiency Virus 
INH              Isoniazid 
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IPT               Isoniazid Prophylaxis Therapy 
IRIS              Immune Reconstitution Inflammatory Syndrome  
MDR-TB Multi Drug Resistant Tuberculosis 
MS-Excel      Micro Soft Excel 
MTB             Mycobacterium Tuberculosis 
NTG             National Treatment Guidelines  
NTP             National TB Control Programme 
PLWHIV       Peoples Living With HIV and AIDS 
ProTest        Promotion of HIV testing 
PTB             Pulmonary TB 
SPSS  Statistical Package for the Social Sciences 
SSA  Sub-Saharan Africa 
TB                Tuberculosis 
UNAIDS United Nations Joint Programme on HIV/AIDS 
UNISA University of South Africa 
VCT             Voluntary Counselling and Testing  
WHO  World Health Organization 
XDR-TB        Extreme Drug Resistant Tuberculosis 
 
1.14        ORGANISATION OF THE REPORT 
 
This dissertation has been organised according to the following five chapters. 
 
Chapter 1 introduced the study and provided background information about TB 
and HIV/AIDS in the world, SSA, Eastern Africa, and Ethiopia in particular.  It 
also highlighted the provision of TB/HIV co-management and HAART in Ethiopia.   
 
Chapter 2 discusses the literature reviewed on TB case detection among HIV-
positive patients and TB/HIV management.   
 
 18 
Chapter 3 describes the research methodology used in collecting data for this 
study. 
 
Chapter 4 presents an analysis of the data collected and a broader discussion of 
the study’s findings. 
 
Chapter 5 discusses the conclusions and limitations of this study and provides 
recommendations for enhancing TB case detection among HIV-positive patients, 
suggestions for improving TB/HIV co-management, and for conducting similar 
studies in future. 
 
1.15   SUMMARY 
 
This chapter provided background information on TB and HIV/AIDS 
internationally, continentally, regionally, and at country level (in Ethiopia).  The 
following topic areas were discussed in detail: the research problem, research 
questions, purpose of the study, research objectives, assumptions underlying the 
study, significance of the study, research methodology, scope and limitations of 
the study, definitions of key concepts, organisation of the report, and its 
conclusion. 
 
Chapter 2 presents a wider discussion of the relevant literature reviewed related 
to this study’s research questions and pertaining to TB/HIV co-management 
globally, in SSA, and in Ethiopia.  
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CHAPTER 2 
LITERATURE REVIEW 
 
 
 
2.1          INTRODUCTION 
                                                    
The literature review covers published and unpublished reports related to 
TB/HIV, HIV/AIDS, TB, ART, TB case detection among PLWHIV, and factors 
associated with TB/HIV collaborative management. Reviewed documents were 
obtained from WHO publications, articles, series publications and journals, 
documents from the FMoH (published and unpublished), TB/HIV-related 
websites, and  journals such as the official Journal of the International AIDS 
Society, Brazilian Journal of Infectious Diseases, American Journal of 
Respiratory and Critical Care Medicine, and the International Journal of 
Tuberculosis and Lung Disease.  The literature review covered the period from 
2002 to 2012. 
 
2.2 TB/HIV CO-MANAGMENT                                                                                     
 
Key concepts of the literature review included: TB case detection among 
PLWHIV, TB/HIV collaborative management, HAART and TB- DOTS (directly 
observed treatment – short course), cotrimoxazole prophylaxis therapy (CPT), 
isoniazid prophylaxis treatment (IPT), HIV voluntary counselling and testing 
(VCT), measurement and indicators of TB/HIV collaboration, and factors affecting 
TB/HIV co-management. 
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2.2.1 Definitions 
 
The terms ‘TB/HIV initiative,’ ‘TB/HIV collaborative activities,’ and ‘TB/HIV co-
management’ are used interchangeably by different authors, and this practice will 
be followed in this dissertation. 
 
The terms ‘TB case detection among PLWHIV,’ ‘TB screening among PLWHIV,’ 
and ‘TB tracing among PLWHIV’ are also used interchangeably by different 
authors, and this practice will also be followed in this dissertation.  
 
According to the WHO and Constella Futures (2007e:6), the phrases ‘TB/HIV’ 
and ‘HIV/TB’ are commonly used to indicate the intersecting epidemic of TB and 
HIV.  A third of the world’s population is infected with MTB, the bacterium that 
causes TB. In 2011, there were an estimated 8.7 million new cases of TB, and 
among these 13% were co-infected with HIV (WHO 2012:2). The term TB/HIV 
refers to this intersection. 
 
Collaborative TB/HIV activities are activities recommended by the interim policy 
of the WHO on TB/HIV to address the dual epidemic of TB and HIV. These 
activities aim to create mechanisms of collaboration between TB and HIV/AIDS 
programmes, reduce the burden of TB among PLWHIV, which includes TB 
screening among PLWHIV, and to reduce the burden of HIV among TB patients 
(WHO 2004a:2).  The WHO and Constella Futures (2007e:10) categorise 
countries according to their TB/HIV collaborative activities. These include: 
 
• Category I: Countries in which the national adult HIV prevalence rate is 
greater than or equal to 1% (generalised epidemic level) or in which the 
national HIV prevalence among a certain population group (such as TB 
patients or injected drug users) is greater than or equal to 5% 
(concentrated epidemic level). These countries should implement all 12 
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collaborative TB/HIV activities, as mentioned in chapter 1 of this 
dissertation. Ethiopia has been categorised into this group. 
 
• Category II: Countries in which the national adult HIV prevalence rate is 
below 1%, but in which there are administrative areas with an adult HIV 
prevalence rate of greater than or equal to 1%. These countries should 
implement all collaborative TB/HIV activities in those administrative areas 
with an adult HIV prevalence rate of 1% or greater, and should implement 
activities as category III countries in other parts of the country. 
 
• Category III: Countries in which the national adult HIV prevalence rate is 
below 1% and in which there are no administrative areas with an adult HIV 
prevalence rate of greater than or equal to 1%. These countries should 
implement the activities aimed at decreasing the burden of TB in PLWHIV 
(intensified TB case finding, IPT, and TB infection control in healthcare 
and congregate settings). 
 
The WHO interim policy on collaborative TB/HIV activities does not call for the 
creation of new specialists or disease control programmes that would address 
TB/HIV co-management. Instead, the argument is made that simple collaboration 
between TB and HIV/AIDS disease programmes, in place of creating a new 
separate disease control programme or integrating the two programmes, should 
be the main method used to deliver collaborative TB/HIV activities (WHO and 
Constella Futures 2007e:11; WHO 2004a:4) . 
 
The term ‘public private mix’ (PPM) refers to the practice of  engaging private 
health care providers of TB/HIV activities in areas with high HIV prevalence in 
order to take advantage of their potential to scale-up collaborative TB/HIV 
activities (WHO 2008e:12). According to the FMoH (2006:1), the term ‘PPM 
TB/HIV’ is defined as public private and public-public partnerships established to 
enhance TB/HIV implementation.  This approach reduces the time between 
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diagnosis and treatment as well as the costs of treatment provided to patients by 
eliminating or reducing the common practice of “shopping” for care. PPM can 
also cut costs to patients by reducing transport expenses and ensuring free 
drugs and other services (WHO 2008e:8) closer to their homes and/or jobs than 
would have been the case without such collaborations.  
 
2.2.2 The concept of TB/HIV co-management and TB case detection among 
PLWHIV 
 
Tuberculosis (TB) is a leading cause of death among PLWHIV. At least one in 
four deaths among PLWHIV can be attributed to TB, and many of these deaths 
occur in areas with limited resource access (WHO 2010:3). Collaborative TB/HIV 
activities are essential to prevent, diagnose, and treat TB among people with HIV 
and HIV among TB patients, and to ensure that HIV-positive TB patients are 
identified and treated appropriately. In recent years, the implementation of 
collaborative TB/HIV activities has been rising globally (WHO 2010:3; FMoH & 
FHAPCO 2007a:15). 
 
According to the WHO (2011:65), until 2010 data on intensified screening for TB 
among people living with HIV and the provision of IPT to those without active TB, 
were requested from national TB programmes (NTPs) on global TB data 
collection forms. It has been noted that the monitoring of access to these two 
interventions at the country level was weaker than for other interventions, such 
as ART.  
 
Moreover, the WHO (2009f:1) has also posited that “… the unprecedented scale 
of the HIV-related TB epidemic demands urgent, effective, and coordinated 
action in order to improve diagnostic, care, and prevention services for people 
living with HIV and TB”. According to the WHO, however, this does not require 
the development of an independent programme for TB/HIV, but rather closer 
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collaboration between existing TB and HIV control programmes to exploit 
synergies, avoid overlap, and address gaps in the services provided. In locations 
where HIV fuels the TB epidemic, collaborative TB/HIV activities are intended to 
reduce the latter disease by expanding the scope of TB and HIV control 
programmes and by improving the quality of provided services. An increasing 
amount of resources is being allocated to collaborative TB/HIV activities.  In 
many countries, innovative pilot projects are in the process of being replaced by 
scaled-up national TB/HIV activities (FMoH 2007b:11).  
 
The WHO reports (2008d:1) have included the provision that as resource-limited 
countries rapidly expand their HIV/AIDS treatment and care programmes, TB/HIV 
is becoming a major public health threat for people living with HIV. Among 
PLWHIV, TB is the most frequent possible life threatening opportunistic disease, 
even for those receiving ARVs. It remains a leading cause of death.  
 
TB control requires and complements the implementation of core HIV control 
interventions and the strengthening of health care systems. In addition, it has 
been recommended that countries should include TB infection control in their 
national infection prevention and control policies, and should maximise synergies 
between programmes that deal with infection prevention and control, especially 
in the case of those focusing on TB and HIV control (WHO 2009:1). 
 
The WHO (2011:68) guidelines recommend TB screening that includes four 
symptoms (current cough, fever, weight loss, and night sweats), as well as the 
provision of IPT if these symptoms are absent. This symptom-based screening 
method has been found to be very effective in accelerating TB screening in 
settings where the prevalence of TB among people living with HIV is 5% or 
higher. 
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2.2.3 Goals of TB case detection among PLWHIV  
 
The goal of TB case detection among PLWHIV is to detect TB as early as 
possible and provide treatment or prophylaxis  to reduce mortality. The WHO has 
reported that efforts will need to be intensified in order to approach the Global 
Plan’s target of providing TB screening to all  those enrolled in HIV care and 
providing IPT to all eligible patients using HIV services by 2015 (WHO 2011:65). 
The WHO has also argued (2009f:4) that the goal of collaborative TB/HIV 
activities should be understood as the reduction of TB and HIV’s scale and scope 
in populations affected by both diseases.  This is to be done through an 
expansion of TB and HIV control programmes. The WHO’s objectives that 
underlie this goal are to establish mechanisms for collaboration between TB and 
HIV control programmes, to reduce the burden of TB amongst people living with 
HIV, and to reduce the burden of HIV amongst TB patients.  
People living with HIV are more likely to be infected with EPTB or sputum smear-
negative TB, especially as their immune-suppression advances. This can result 
in misdiagnosis and delayed diagnosis, and, in turn, higher mortality rates. 
Irrespective of the epidemic’s location, the WHO recommends HIV testing for all 
patients of all ages who arrive at a clinic with signs or symptoms that suggest TB, 
whether or not TB is suspected or has already been confirmed  (WHO 2004b:75; 
WHO 2007b:46; WHO 2008a:46). 
 
2.2.3.1 Establishing mechanisms for TB case detection among PLWHIV  
 
TB case detection among PLWHIV could be made operational through the 
establishment of mechanisms for TB/HIV collaboration. According to the 
Republic of Tanzania’s Ministry of Health (RTMoH 2008:7), for example, all 
patients at HIV clinics should be screened for TB during each visit, and referred 
to the laboratory for diagnosis if TB is suspected.  If TB is diagnosed, the patient 
should be referred to a TB clinic for treatment. At TB clinics, moreover, TB 
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patients should be tested for HIV, while making sure that they are treated first for 
TB and then assessed for ART by HIV officers.  
 
The Ethiopian TB/HIV Guidelines (FMoH & FHAPCO 2007a:23) also mandate 
regular TB screening among HIV-positive patients at every stage of the disease 
(FMoH 2008a:25). This is aimed at reducing the burden of TB among PLWHIV. 
An HIV-positive patient is eligible to start IPT after the exclusion of active TB 
(which would require immediate TB treatment). TB screening is conducted at HIV 
clinics. Based on the results of this screening, patients will start TB prophylaxis 
with INH if the screening result is negative, or will be referred to a TB clinic for 
immediate TB treatment if the HIV patient is diagnosed as suffering from TB. 
 
National and international bodies have additionally made the case that TB/HIV 
collaboration treatment can also be established though coordinating bodies, as 
well as through surveillance of HIV conducted among TB patients, joint planning, 
and monitoring and evaluation of treatment methods (WHO 2009f:5). 
 
2.2.3.2 Decreased burden of TB among HIV-positive persons 
 
Meta-analyses of randomised controlled trials (RCTs) have shown that, when 
compared to placebos, TB therapy (comprising any anti-TB drugs) reduces the 
risk of active TB by 32% amongst PLWHIV (relative risk [RR] 0.68, 95% 
confidence interval [CI]: 0.54 to 0.85), and by 62% (RR 0.38, 95% CI: 0.25 to 
0.57) amongst those who are tuberculin skin test positive. IPT reduces the risk of 
TB by 33% (RR 0.67, 95% CI: 0.51 to 0.87) among HIV-positive patients with 
both positive and negative skin tests, and by up to 64% (RR 0.36, 95% CI: 0.22 
to 0.61) among those with positive tuberculin skin tests (WHO 2010:5). 
 
Data from the WHO (2010:18) have demonstrated the risks of TB-associated 
immune reconstitution inflammatory syndrome (IRIS), which is an ART-related 
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complication. High incidence rates of identified TB during highly active anti-
retroviral therapy (HAART) programmes in resource-poor countries have also 
been observed. These rates are likely to include both undiagnosed latent TB 
existent at the time of HAART initiation, and subclinical TB that developed during 
the IRIS period. IRIS is a well described condition that commonly follows the 
initiation of HAART in PLWHIV who are also harbouring chronic intracellular 
infections. It has been described together with MTB and usually manifests itself 
within 2-11 months with a particular set of symptoms (WHO 2004b:154; WHO 
2010:18).     
 
Mortality rates from TB are higher among HIV-positive than among HIV-negative 
patients (WHO 2009b:67). Case-fatality is particularly high among people living 
with HIV together with smear-negative PTB and EPTB, as these patients are 
generally more immune-suppressed than those with smear-positive TB. 
However, case-fatality rates have been reduced among TB patients who 
received concurrent ART and anti-TB treatment (WHO 2009b:68). IPT has also 
been determined to be effective among people living with HIV because it reduces 
the risk of developing active TB (WHO 2009c:12). The incidence of TB also 
decreased in HIV-positive patients receiving ART.  
 
Health workers are more exposed to TB than the general population.  As a result, 
HIV-positive health workers have been identified as a priority group for IPT. 
According to the WHO (2009c:12), all healthcare workers should be given 
appropriate information and encouraged to undergo TB diagnostic procedures if 
they have signs and symptoms suggestive of TB. Healthcare workers should be 
given appropriate information and encouraged to undergo HIV testing and 
counselling. If they are diagnosed with HIV, healthcare workers should be offered 
a package of prevention, treatment, and care that includes regular screening for 
active TB and access to ART. Based on a full medical evaluation, health workers 
should be put on either IPT or, if diagnosed with active TB, a full regimen of anti-
TB treatment. HIV-positive health workers should also avoid working with 
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patients with known or suspected TB. In particular, they should not work with 
patients with MDR-TB and XDR-TB.  If needed, these healthcare workers should 
be relocated from positions where an exposure to untreated TB is high to lower 
risk areas. 
 
2.2.4 The scope of TB case detection among PLWHIV and TB/HIV co-   
management   
 
The WHO (2009e:1) has reported that in 2008 almost 1.4 million TB patients 
around the world were tested for HIV and provided with HIV prevention, 
treatment and care services.  This is an increase of 1.2 million from 2007. 
Amongst HIV-positive TB patients, 200 000 or approximately two thirds of the 
sample, were given co-trimoxazole treatment (CPT), while one third (100 000 
patients) were given ART.  In 2008, the number of PLWHIV who were screened 
for TB more than doubled from 600 000 in 2007 to 1.4 million.  At the same time, 
however, this figure represented only a small fraction of the 33 million people 
estimated to be living with HIV worldwide. More worryingly, in 2008 only 56 000 
PLWHIV, began IPT, and TB control measures remained under-implemented in 
many regions, particularly in SSA (WHO 2009e:2).  
 
The FMoH and FHAPCO (2007a:17) and the WHO (2008:1; 2009f:28) defined 
the scope of collaborative TB/HIV activities in the following terms:  
 
Establishing mechanisms for collaboration by  
• Setting up a co-ordinating body for TB/HIV activities which would be 
effective at all levels 
• Conducting investigations of HIV prevalence among TB patients 
• Carrying out joint TB/HIV planning 
• Conducting monitoring and evaluation processes 
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Decreasing the burden of TB in people living with HIV by: 
• Establishing intensified TB case-finding 
• Introducing IPT 
• Ensuring TB infection control in health care and congregating settings 
 
Decreasing the burden of HIV in TB patients by:  
• Providing HIV testing and counselling 
• Introducing HIV prevention methods 
• Introducing CPT 
• Ensuring HIV/AIDS care and support 
• Introducing ART 
 
2.2.5  Standard interventions for TB/HIV co-management 
 
In addition to the collaborative TB/HIV activities defined by international 
organisations, such as the WHO and national ministries, the following 12 
standard interventions, for TB/HIV co-management, have been compiled from a 
selection of relevant literature sources:  
 
2.2.5.1 Establishing a coordinating body for TB/HIV co-management  
 
Coordination is a central element of any process aimed at reaching policy 
consensus, developing joint strategic plans, mobilising resources, building 
capacity, or implementing and monitoring collaborative TB/HIV activities.  This is 
especially true of matters such as boosting TB case detection among PLWHIV. 
In order to guarantee functional coordination, it becomes necessary to provide a 
mechanism for coordinating collaborative TB/HIV activities at all levels in a 
country: at the national, district and facility level. In addition, representatives from 
different departments and ministries involved in the activities of the TB/HIV 
coordinating body will need to meet regularly, if actual and effective coordination 
is to be provided (FMoH 2008b:1).  
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Evidence from operational research (FMoH & FHAPCO 2007b:12; Godfrey-
Faussett et al 2002:80; WHO 2004a:3) has shown that having TB/HIV 
coordinating bodies operating at all levels is a feasible task. This ensures 
commitment and programmatic ownership.  This is particularly true when 
stakeholders from all relevant HIV/AIDS and TB control programmes participate. 
This sort of coordinating body can also address governance issues in the 
implementation of joint TB/HIV plans (Godfrey-Faussett et al 2002:80; WHO 
2004a:3). 
 
2.2.5.2 Surveillance of HIV prevalence among TB patients 
 
Ideally, any surveillance of HIV prevalence should include all new TB patients 
who have been diagnosed according to international standards. There are three 
main methods for the surveillance of HIV among TB patients (Talbot et al 
(2001:710; WHO 2004a:3):  
• Routine HIV testing data can form the basis for a reliable surveillance 
system during all stages of the HIV epidemic (low-level, concentrated, and 
generalised), assuming that high surveillance coverage levels have been 
achieved and maintained. These routine data can be calibrated by 
periodic (special) or sentinel surveys. 
• Sentinel surveys collect information in a regular and constant way from a 
predetermined number of people in targeted locations, including particular 
groups who are of special interest to the surveillance conducted. Some 
difficulties can arise during sentinel surveillance as a result of a 
representative mismatch between the sampled group and the general 
population. Sentinel survey methods are usually developed using unlinked 
anonymous testing methods.  Such methods include the use of blood 
samples that have been collected for other purposes and stripped of all 
identifying markers. 
• Periodic special surveys are also of use, especially where the prevalence 
of HIV among TB patients has not been previously estimated. These can 
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form an important part of initial situation analyses. Periodic surveys, 
employing representative sampling methods and appropriate sample 
sizes, can provide accurate estimates of the burden of HIV in TB patients. 
 
According to Talbot et al (2001:710) and the WHO (2004a:3), evidence from 
descriptive studies have demonstrated that HIV surveillance among TB patients 
is a critical activity needed in order to understand the epidemic’s development, as 
well as to create sound strategies to address the dual TB/HIV epidemic (Bowen  
et al 200:1488; Talbot et al 2001:710).   
 
2.2.5.3 Joint TB/HIV planning 
 
Joint planning involving representatives of agencies, clinics, and other institutions 
involved in all levels with the treatment of both HIV and TB, is fundamental for 
any TB/HIV collaboration. A joint plan must contain the following components: 
clear definitions of the roles and responsibilities of the TB and HIV treatment 
regimes, delineation of the implementation of all 12 collaborative TB/HIV 
activities, and collaborative development of TB/HIV guidelines for prevention, 
diagnosis, treatment and care.  This last category ought to include activities 
related to advocacy, communication and social mobilisation tools, joint resource 
mobilisation for collaborative TB/HIV activities, and joint strategies for human 
resource departments to ensure adequate staff for the delivery of collaborative 
TB/HIV activities.  Joint training on TB and HIV for all health-care workers should 
be provided to enhance effective communication and advocacy strategies for TB 
and HIV control and implementation programmes . 
 
Third party research findings (Floyd 2003:83; WHO 2004a:4; WHO 2009f:13) 
have shown that effective and efficient implementation of collaborative TB/HIV 
activities depends on joint planning and implementation conducted by the TB and 
HIV/AIDS programmes concerned. This process, in turn, requires close 
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collaboration between community care services and government health 
institutions. 
 
2.2.5.4    Monitoring and evaluation of collaborative TB/HIV activities  
 
The presence of an integrated system for the coordination and evaluation of 
collaborative HIV activities is a very important element of a broader series of 
guidelines or recommendations. Routine monitoring includes data collection 
about TB/HIV indicators and the regular evaluation of all collaborative activities 
forming the foundation for a TB/HIV collaborative monitoring and evaluation 
system.  
 
2.2.5.5   Intensified TB case-finding among PLWHIV 
 
In 2011, 1.1 million (13%) of the 8.7 million people who developed TB globally 
during that year were HIV-positive; 79% of these HIV-positive TB cases were in 
the African region (WHO 2012:1). The percentage of notified TB patients with a 
documented HIV test result in SSA rose from 60% in 2010 to 69% in 2011.  In 
2011, 46% of those tested were HIV-positive, ranging from 8% in Ethiopia to 77% 
in Swaziland. Worldwide, 40% of TB patients notified in 2011 had a documented 
HIV test result, up from 33% in 2010 and more than ten times the level of 2004. 
Of those individuals enrolled in HIV care in 2011, a total of more than 3.2 million 
were reported to have been screened for TB, an increase of 39% from the 2.3 
million screened in 2010. Amongst those found to be without active TB, 450 000 
were provided with IPT, more than twice the number of people who had been 
given IPT in 2010 (WHO 2012:83). 
 
Effective TB/HIV collaboration is usually characterised by a system capable of 
monitoring the notification of TB amongst PLWHIV. In general, HIV care and 
treatment registers (pre-ART and ART) record TB treatment, which can then be 
aggregated in quarterly reports that can provide numbers verifying the proportion 
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of people enrolled in HIV care who had started TB treatment. These figures can 
also include rates of intensified TB case-finding for those who were found to be 
HIV-positive during testing.  They can also reveal intensified TB case-finding for 
PLWHIV at all levels of care, and formal referral mechanisms set up between 
HIV diagnostic and care services and TB diagnostic and treatment services.  
 
Research (WHO 2004a:7; 2008d:4; 2010:11) has pointed to intensified case-
finding’s importance in any collaborative activities. Intensified case-finding and 
treatment of TB among HIV-positive patients can interrupt the disease 
transmission, reduce mortality, decrease the risk of nosocomial TB transmission, 
and allow the provision of IPT to HIV-positive patients. According to Burgess et al 
(2001:15) and Nachega et al (2003:17), intensified case-finding is cost effective 
and feasible. According to the WHO (2012:11), any intensified case-finding 
mechanism used to promptly detect TB and prevent TB among PLWHIV should 
also include regular screening for TB and obligatory IPT for those without active 
TB. 
 
2.2.5.6    Isoniazid preventive therapy (IPT) for PLWHIV 
 
Isoniazid is generally given to patients with latent MTB infections in order to 
prevent progression to active TB disease. The exclusion of active TB is critically 
important before this therapy can be started. Isoniazid is given to patients daily 
as self-administered therapy for six to nine months. Since HIV-infected people 
can develop TB before ART is indicated, and as there is no evidence arguing 
against the combined use of these drugs, ART does not preclude the use of IPT. 
However, IPT has the potential disadvantage of an increased risk of drug toxicity 
and the possible emergence of drug resistance (WHO 2004:201).  
 
IPT has been found to be more effective and safer in terms of preventing latent 
TB than regimens based on rifampicin or pyrazinamide (WHO 2004a:7). 
Randomised trials have demonstrated that IPT is effective in reducing the 
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incidence of TB and TB mortalities amongst HIV-positive patients with a positive 
tuberculin skin test (LoBue & Moser 2003:443; WHO 2004a:7; WHO 2010:5). IPT 
has also resulted in cost savings in medical care and in the reduction of social 
costs in SSA (Terris-Prestholt, Kumaranayake, Ginwalla, Ayles, Kayawe, Hillery 
& Faussett 2008:5). However, this therapy requires several particular steps to be 
taken, including the identification of HIV-positive patients, screening to exclude 
active TB, and IPT adherence. For these reasons, it might be possible to 
question the feasibility of implementing IPT in developing countries. In some 
studies, the combined use of ART and IPT was reported without conclusive 
evidence about the overall treatment effectiveness (Girardi et al 2000:1985; 
Santoro-Lopes et al 2002:543; WHO 2004a:7). The results of future studies 
assessing the effectiveness of the joint treatment will need to be closely followed 
in order to provide proper guidance for on-going policy development (LoBue 
2003:443; Wilkinson 2000:4).  
 
2.2.5.7   Control of TB infections in healthcare and congregate settings 
 
Healthcare and congregate settings (such as prisons, police stations, and military 
barracks) – places where people with TB and HIV are frequently crowded 
together - TB infection rates have been consistently increased (WHO 2004a:8). 
Measures to reduce TB transmission in such environments include 
administrative, environmental, and personal protection measures, all  aimed at 
generally reducing the exposure of healthcare workers, prison staff, police and 
their clients, as well as any other individuals living in congregate settings. 
Administrative measures should include early TB detection, diagnosis, and 
treatment of TB suspects, particularly those with PTB, as well as the separation 
of PTB suspects from others in the congregate population until diagnosis has 
been confirmed or excluded. Environmental protections should include 
maximising natural ventilation, and using ultraviolet radiation (if applicable). 
Personal protection methods ought to include the protection of HIV-positive 
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individuals from possible exposure to TB (for example, the transfer of a HIV-
infected worker from medical wards) and the provision of IPT. 
 
Overall, there does seem to be an increased risk of TB infection among health 
workers, medical and nursing students who have contact with patients, prisoners, 
and soldiers in military barracks, exacerbated by the HIV epidemic (WHO 
2003b:281). HIV promotes the progression to active TB in people with recently 
acquired infections, or with latent TB infections (Miles 2003:174; WHO 2002:296; 
WHO 2003b:281).  
 
2.2.5.8   Providing HIV testing and counselling for TB patients 
 
HIV testing and counselling for TB patients, using rapid tests, offers an entry 
point for an ongoing continuum of prevention, care, support, and treatment for 
HIV/AIDS as well as for TB (WHO 2004a:8). This testing provides benefits that 
will accrue to the patient, his or her family, and the community in which the 
patient lives. HIV testing should be readily available, and should include both 
provider-initiated and voluntary testing. Informed consent should be obtained 
from all of those undergoing testing and the confidentiality of patients should be 
maintained.  
 
Increases in HIV testing amongst TB patients have proven to be higher than 
expected in some areas.  For example, a study in rural Malawi has shown an 
88% acceptance level of HIV tests amongst TB patients (Godfrey-Faussett et al 
2002:939; WHO 2003a: 336; Zachariah  et al 2003:1053). In addition, it should 
be noted that the cost-effectiveness of voluntary HIV counselling and testing 
improves significantly when this testing is aimed at populations with a high 
prevalence of HIV (Sweat et al 2000:113). 
 
2.2.5.9   Introducing HIV prevention methods for TB patients 
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As the WHO has indicated (2004a:9), the reduction of sexual, parenteral, and 
vertical transmissions of HIV is most effectively built upon broad HIV/AIDS 
education programmes. Measures used to reduce the sexual transmission of HIV 
include the promotion of safer and more responsible sexual behaviour and 
practices, as well as education about the delayed onset of sexual activity, a 
reduced number of sexual partners, the effective use of condoms (male and 
female), and the diagnosis and treatment of other sexually transmitted infections 
(STIs). On the other hand, activities that can be applied to reduce parenteral HIV 
transmission include ensuring blood supply safety and the use of sterilised 
injection and surgical equipment in medical settings. Amongst intravenous drug 
users, harm-reduction strategies such as wider access to sterile needles, drug-
dependence treatments, and outreach services aimed at the reduction of drug 
use are of particular value. Vertical transmission of HIV can also be reduced 
through the provision of antiretroviral drugs to pregnant women and their children 
as an element of effective prevention of mother-to-child transmission (PMTCT) 
programmes (Wilkinson & Rutherford 2001:2). 
 
A review of available evidence (Creese et all 2002:1635) has shown that HIV 
prevention methods are cost effective compared to other treatment regimes. The 
provision of HIV prevention methods within TB control programmes, as well as 
the effective referral of patients to AIDS programmes, is feasible in settings with 
a high joint prevalence of TB and HIV. The improved treatment of STIs has 
reduced the HIV incidence in environments characterised by the HIV epidemic’s 
emergent status (Godfrey-Faussett et al 2002:939; Wilkinson, Rutherford 
2001:2). 
 
2.2.5.10  Introducing co-trimoxazole preventive therapy (CPT) for TB/HIV   
     patients 
 
Co-trimoxazole preventive therapy has been promoted by the WHO and UNAIDS 
(FMoH 2006:1; WHO 2004a:9) as a method of preventing of several secondary 
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bacterial and parasitic infections in eligible adults and children living with 
HIV/AIDS in Africa. TB/HIV patients are within this category and are thus eligible 
for this therapy. According to Godfrey-Faussett (2003:1079) and Zachariah et al 
(2001:843), evidence from randomised controlled trials of CPT has demonstrated 
reduced mortality rates among HIV-positive smear-positive TB patients and 
reduced hospitalisation and morbidity rates among PLWHIV when CPT is 
applied.  In addition, other non-randomised and operational studies have shown 
that CPT is feasible, safe, and reduces mortality rates among a wide cross-
section of TB patients (Godfrey-Faussett 2003:1079; Zachariah et al 2001:843; 
Zachariah et al 2002:1046).  
 
2.2.5.11   Ensuring HIV/AIDS care and support for TB patients  
 
For people living with HIV/AIDS, access to health care is a basic human right and 
includes the provision of clinical care as part of a continuum of a comprehensive 
AIDS care (WHO 2004a:10). This approach to AIDS care includes clinical 
management (prophylaxis, early diagnosis, rational treatment, and follow-up care 
for opportunistic infections), nursing care (including promoting hygiene and 
nutritional support), palliative care, home care (including education for home care 
providers and patients' relatives), counselling, and social support. People living 
with HIV/AIDS, who are undergoing or who have completed TB treatment, are 
provided with a full continuum of care and support, as engendered by the client 
referral system. 
 
Linking HIV/AIDS prevention to care and support regimes generates synergies 
and strengthens HIV/AIDS programmes (UNAIDS 2003a:30). Farmer et al 
(2001a:404) have additionally stated that directly observed antiretroviral therapy 
given to people living with HIV/AIDS, when modelled on successful similar TB 
control efforts, has been useful as a way of extending moral and social support to 
people living with HIV/AIDS. According to the WHO (2003a:311), operational 
research  has shown that collaboration between TB and HIV programmes can 
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effectively scale up the delivery of care and support activities to HIV-infected TB 
patients (Farmer et al 2001b:408; UNAIDS 2002:29;WHO 2003a:31). 
 
2.2.5.12   Providing antiretroviral therapy (ART) for TB/HIV patients  
 
Studies have found that ART improves the quality of life and greatly improves the 
rate of survival amongst PLWHIV (WHO 2004a:10). The availability of ART can 
also serve as an incentive for people to be tested for HIV, since it transforms HIV 
infection from a death sentence into a chronic condition. Of course, it is a lifelong 
treatment requiring a high adherence rate (of at least 95%), without which long-
term benefits are difficult to achieve and the development of drug resistant HIV 
strains could occur. 
 
Other researchers have found that there is evidence for potent ARVs’ ability to 
reduce the incidence of TB in HIV-positive persons by more than 80% (Badri, 
Wilson, Wood 2002:2059; Girardi et al 2000:1985). However, in order for ART to 
prevent a significant portion of TB cases from developing, ART must be initiated 
early in the course of a HIV infection, and a high rate of compliance is required. 
The initiation of ART in HIV-infected TB patients can result in the temporary 
worsening of TB symptoms in up to 30% of the patients in the developed world 
(Farmer et al 2001b:404; Williams & Dye 2003:1126). Observational studies 
(Farmer et al 2001b:1145; Liechty & Bangsberg 2003:1383; Mitty et al 2003) 
have in some cases proposed that TB DOT programmes be used as a model for 
ART delivery. At the same time, however, there have been conflicting opinions 
about this strategy, especially because of a scarcity of evidence (Liechty & 
Bangsberg 2003:1388).  
 
In conclusion, TB/HIV collaboration programmes’ goals are best achieved 
through the effective and joint implementation of DOTS, enhanced HIV 
prevention and care, and the delivery of the 12 standard collaborative TB/HIV 
activities described above. These collaborative activities address the overlap 
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between the intersecting TB and HIV epidemics, and should be carried out as 
parts of a broader health-sector response to the dual TB/HIV epidemic. They will 
be more successful, when combined with the effective implementation of national 
HIV and TB control strategies, based on international guidelines.  
 
2.2.6   The relationship of TB and HIV clinical management 
 
According to the Ethiopian TB/HIV Guidelines (FMoH & FHAPCO 2007a:23), an 
HIV-positive patient is eligible to start IPT after the exclusion of active TB (which 
would require immediate TB treatment). Regular screening for TB among HIV-
positive patients, at every stage of the disease, is also seen as a key TB/HIV 
collaborative activity (FMoH 2008a:25), which is aimed at reducing the burden of 
TB in PLWHIV. Screening for TB is conducted at HIV clinics. Based on the 
results of the screening, patients start TB prophylaxis with INH if the screening 
result is negative or will be referred to the TB clinic for effective treatment of TB if 
the HIV patient is diagnosed as suffering from TB. 
 
The Ethiopian ART Guidelines (FMoH 2006: 24) describe eligibility for ART for 
TB patients as follows: 
• ART is recommended for all TB patients at WHO clinical stage III with 
CD4 counts < 350 cells/mm3, and TB patients with WHO clinical stage 
IV defining conditions irrespective of their CD4 count   
or 
• In cases where CD4 count is not possible, all TB patients are eligible 
for ART 
 
In addition, the Ethiopian TB/HIV Guidelines (FMoH & FHAPCO 2007a:23) 
dictate that an HIV-positive patient is eligible to start IPT after active TB has been 
excluded. According to these guidelines (FMoH & FHAPCO 2006: 12), all TB/HIV 
 39 
co-infected patients are eligible to start CPT, irrespective of their CD4 cell count 
or stage of their disease.  
The WHO, however,  has argued that the  optimal time to start ART relative to 
the start of TB therapy is not yet clear.  At the same time, however, one 
randomised controlled trial has provided some evidence for early initiation of ART 
in terms of reduced all-cause mortality, improved TB outcomes, and a reduced 
incidence of IRIS (WHO 2009b:70).  
 
It has been additionally found that when TB is diagnosed in patients already 
receiving ART, TB treatment should be started immediately (WHO 2009b:71). 
There are two more issues to consider in these cases.  First, it must be 
established whether or not ART will need to be modified as a result of drug to 
drug interactions, or in order to reduce the potential for overlapping toxicities.  
Second, it will need to be determined whether or not the existence of active TB in 
a HIV-positive patient on ART constitutes an ART failure that would require a 
change in the ART regimen. 
 
This touches upon broader concerns related to the overlap of ART and TB 
treatment regimes.  Outbreaks of drug-resistant TB (MDR TB) amongst HIV-
positive patients have been widely documented in nosocomial and other 
congregate settings, but little information has been made available about the 
association between HIV and drug-resistant TB on a wider population level 
(WHO 2009d:11). Two main reasons have been found, however, as to why drug-
resistant TB might be associated with HIV. The first is the documented 
acquisition of isolated rifampicin resistance among HIV-positive patients under 
treatment for TB, although this fact remains possible to explain as a result of 
disruptions in therapy. Anti-TB drug malabsorption has also been documented in 
patient cohorts with a high prevalence of HIV, which suggests that HIV-positive 
TB patients might be at greater risk of acquiring drug resistance. The second 
reason that could explain the higher than usual levels of MDR TB amongst HIV-
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positive patients is related to their exposure. HIV-positive patients and drug-
resistant TB patients might have similar risk factors, such as a history of  
hospitalisations, which in turn might mean that HIV-positive TB patients are at a 
higher risk of exposure to resistant forms of TB than HIV-negative patients. 
 
Further research has pointed to the equanimity of joint therapy. In one study 49 
HIV-positive patients, most of whom were receiving ART and who also had active 
TB, were treated with Rifampin 600mg, Isoniazid 400mg and Pirazinamide 2g 
daily (Dianna et al 2004:1). These patients also received ARVs, consisting of 
Efavirenz (600mg/day), plus 2 NRTIs. All the patients were followed up  for at 
least 24 months.  The non-concomitant ARV regimen was introduced at least 
three weeks after the beginning of TB treatment. Severe adverse reactions to the 
joint treatment included skin rashes (2), toxic hepatitis (6), IRIS (7), and four 
deaths. The study concluded that efavirenz at a daily dose of 600 mg was a 
sufficient and safe treatment for HIV/TB patients using a regimen that contains 
rifampicin. 
 
2.2.7 Factors affecting TB case detection among PLWHIV and TB/HIV co- 
management  
 
The impact of TB screening on PLWHIV has proven hard to estimate (WHO 
2012:81). While the frequency of TB screenings has been shown to determine 
how early TB diagnosis can be made, compared to a lack of screening 
altogether, no global data on the frequency of such screenings has been made 
available.  
 
The WHO (2007c:36-38) has indicated that HIV/AIDS affects the prevention and 
control of TB in numerous ways, including through an increase in the number of 
suspected TB cases, the disease’s impact on human and health infrastructure 
resources, the provision of diagnostic services and case management, the risks 
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of nosocomial TB infections and MDR, increased possibilities for low staff morale 
at healthcare institutions, and increased mortality rates. An individual infected 
with HIV, can be affected by TB in many ways. TB boosts HIV replication, which 
leads to an increased viral load. TB also increases the occurrence of other 
opportunistic infections, because of the increased viral load resulting from TB 
infections. TB patients who are HIV positive thus have an increased chance of 
getting AIDS-defining illnesses, as well as infecting other people with ART-
resistant HIV strains. The management of TB and HIV co-infected patients is also 
challenging because of pill burden, increased adverse effects, drug-to-drug 
interactions and IRIS (WHO 2004:36-39).  
 
When working in populations where HIV/TB is common, health services have 
been reported to struggle with the large and rising number of TB cases (WHO 
2004c:32). HIV/AIDS affects the prevention and control of TB.  This includes the 
simple increase in possible TB carriers and TB patients, which in turn impacts on 
human and infrastructure resources in the health sector, services for diagnosis 
and case-holding, the risk of nosocomial TB infections and the risk of MDR TB 
cases, the possibility for lowered staff morale, and increased mortality rates. On 
an individual level, infection with HIV and the presence of TB can have various 
effects. TB increases HIV replication, which leads to an increased viral load. In 
addition, TB increases the occurrence of other opportunistic infections (WHO 
2004c:34), aggravating the patient’s general illness and hastening the 
development of AIDS-defining illnesses. 
It has been recommend by the British HIV Association that if HIV treatment is 
started in patients who are on anti TB therapy, then HAART might need to be 
modified. TB treatment should be modified if a patient has developed intolerance 
to, or has severe toxicity from, HIV drugs, or if there is evidence of genotypic 
resistance to specific HIV drugs, which would limit HAART therapy to agents that 
are unlikely to interact with anti TB therapy. In addition, a cohort study in Ethiopia 
indicated that HIV-infected Ethiopian patients, who had developed TB, already 
had low CD4 counts and high viral loads prior to their TB diagnoses. The viral 
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load did not decrease following TB treatment, leading to these patients’ poor 
overall prognosis (Wolday et al 2003:1). 
2.2.8 Measuring effective TB case detection and TB/HIV collaboration  
 
Information about TB screening and IPT has in the past few years been collected 
through the UNAIDS monitoring system (WHO 2012:79). This system’s data 
helped to explain why fewer countries reported data on TB screening and the 
provision of IPT in 2011 than in 2010. Recording and reporting TB screening 
among people living with HIV, and the provision of IPT to those without active 
TB, are activities that pose challenges in many countries. Further efforts will be 
needed to facilitate and improve the tracking information on both national and 
global levels. From 53 countries that reported data to the UNAIDS system, 3.2 
million people were recorded as having enrolled in HIV care and having been 
screened for TB during 2011, compared to 2.3 million from 71 countries in 2010 
(WHO 2012:80). 
 
However, since the publication of the WHO’s first policy guidelines on 
collaborative TB/HIV activities in 2004, considerable progress has been made in 
terms of implementing the recommended package of interventions. If analysis is 
extended through 2011, and a full spectrum of four interventions are considered 
– ART for TB patients living with HIV, CPT for HIV patients with TB, IPT for early 
case HIV-positive patients, and systemic TB screening and diagnosis amongst 
HIV-positive patients – then striking estimates might become apparent about the 
number of lives saved as a result of the coordinated activities.  Based on 
information from the WHO, more than 1.3 million lives were saved between 2005 
and 2011.  During 2011 alone, more than 400 000 lives were saved, a significant 
increase from the 50 000 reportedly saved as a result of the coordinated 
activities in 2005 (WHO 2012:81). 
 
It has been effectively argued that collaborative TB/HIV activities should be 
included as part of both TB and HIV control programme reviews.  This process 
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should bring together key staff from both programmes. Reviewers should ensure 
that review findings are shared with both parties concerned with these 
programmes.   
 
Table 2.1:  Features of a legitimate monitoring and evaluation system of 
HIV and TB collaboration 
Monitoring & Evaluation (M&E) unit 
 Dedicated personnel overseeing health service M&E  
 A budget for M&E (10% of total budget) 
 Formalised links with partners  - research institutions, NGOs, donors, and those in the private sector  
 Data processing and statistical expertise from the M&E unit or an affiliated unit 
 Data dissemination expertise from the M&E unit or an affiliated unit 
 Development and maintenance of local M&E human resource capacity  
 Regular and independent programme reviews  
Clear goals  
Well-defined national programme aims, objectives, activities, and targets 
Regular evaluations of the progress achieved in implementing national M&E plans 
Guidance given to districts and regions or provinces on M&E 
Guidelines provided for the linking of M&E to the private and other sectors 
Coordination between national and donor M&E needs 
Indicators 
A set of priority core indicators for different levels of M&E 
Indicators that are comparable between themselves over time 
Indicators that are comparable between geographical areas within a country and between countries 
Data collection and analysis 
A national-level data collection and analysis plan 
A logical flow of data from service delivery to national level 
A plan to collect data and analyse indicators at different levels of M&E 
Data dissemination and use of results  
A national-level data dissemination plan with clear guidance on how information 
can be used for programme improvement at all levels 
A well-disseminated and informative annual M&E report 
Annual meetings that will disseminate and discuss M&E and research findings with policy-makers and 
planners, including programme implementation reviews  
A centralised database or library for all TB- and HIV-related data collection, including on-going research 
Coordination between national and donor M&E dissemination needs 
(WHO 2009f:8) 
 
According to the WHO’s standards (2009f:14), effective TB/HIV collaboration can 
be measured according to the following indicators:  
• The percentage of TB patients who had an HIV test result recorded in the TB 
register 
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• The number of registered TB patients with documented HIV status in the TB 
register who are HIV-positive, expressed as a proportion of the total number 
of all registered TB patients with documented HIV status over the reporting 
period 
• The number of HIV-positive TB patients who have started and are continuing 
previously initiated CPT TB treatment, expressed as a proportion of all HIV-
positive TB patients registered over the reporting period 
• The number of HIV-positive TB patients enrolled in HIV care services during 
TB treatment, expressed as a proportion of the total number of HIV-positive 
TB patients 
• The number of HIV-positive TB patients who have started or are continuing 
previously initiated ART that is occurring during TB treatment, expressed as a 
proportion of all HIV-positive TB patients registered over the reporting period 
• The number of adults and children enrolled in HIV care whose TB status was 
assessed and recorded during their last visit during the reporting period, 
expressed as a proportion of all adults and children enrolled in HIV care and 
seen for care in the reporting period 
• The number of adults and children enrolled in HIV care who have started 
treatment, expressed as a proportion of adults and children enrolled in HIV 
care during the reporting period 
• The percentage of estimated HIV-positive  patients with TB infections that 
have received treatment for TB and HIV 
• The number of adults and children who are newly enrolled in HIV care, who 
have started treatment for latent TB infection (IPT), expressed as a proportion 
of the total number of adults and children newly enrolled in HIV care during 
the reporting period 
• The number of health-care facilities providing services to people living with 
HIV, with demonstrable infection control practices that include TB control, 
expressed as a proportion of the total number of health-care facilities 
evaluated 
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• The number of health-care workers employed in facilities providing care for 
people living with HIV who develop TB in one year, expressed as a proportion 
of the total number of health-care workers employed in facilities providing 
care for people living with HIV during that same year 
 
A national TB and HIV policy should reflect international policy guidance on 
collaborative TB/HIV activities (WHO 2009f:22). For this to occur, the content of a 
government’s TB or HIV policies, plans, and guidelines should be analysed and 
compared with a checklist of key policy components. According to the WHO 
(2009f:23), a national policy is considered to be complete if it contains the 
following 14 key components: explicit recognition of the potential impact of TB 
mortality rates on people living with HIV 
•  inclusion of representatives from the National TB Program (NTP) in the 
planning process of the National HIV/AIDS Control Program (NACP), and vice 
versa 
• surveillance of HIV’s prevalence amongst TB patients that is consistent with 
international recommendations. 
• advocacy, communication, and social mobilisation (ACSM) strategy for HIV, 
including appropriate information about TB, and vice versa.  
• training for those working with HIV patients should include appropriate 
information about TB, and vice versa 
• regular and intensive TB case-finding is recommended for all PLWHIV 
• ART is provided for all eligible HIV-positive TB patients in accordance with 
national protocols 
• HIV-positive TB patients have access to a full continuum of care for people 
living with HIV 
• CPT is provided for all HIV-positive TB patients and all people living with HIV 
in accordance with international guidelines 
•  Access to diagnosis for and treatment of TB is part of a basic package of 
care for people living with HIV 
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•  Treatment of latent TB infection is offered to all people living with HIV in 
accordance with international guidelines 
•  A national TB and HIV coordinating body, technical advisory committee, or 
task force should be established 
• HIV testing and counselling are routinely offered to all TB patients  
• A well-established and functioning infection control policy and monitoring 
system. 
 
2.3         SUMMARY  
 
This literature review emphasised the importance of TB case detection amongst 
PLWHIV, as well as the implementation of TB/HIV co-management. 
Implementation of co-management is essential in a country like Ethiopia in order 
to ensure high quality TB/HIV management. Quality TB/HIV care is necessary to 
suppress the HIV virus to undetectable levels and cure TB.  Together, these 
treatments can increase immunological responses and enable patients to 
achieve a better quality of life.  Although the measurement of treatment’s quality 
is not an easy process, the results of different studies have demonstrated that 
the implementation of TB/HIV co-management, including enhanced TB case 
detection among PLWHIV, can significantly improve patients’ quality of life and 
notably decrease TB/HIV’s joint mortality rates. It is extremely important to attain 
and maintain high levels of collaboration between HIV and TB programmes for 
the effective management of these two diseases.  
 
Chapter 3 will address the research methodology used to study TB case 
detection among PLWHIV in one hospital in Ethiopia.  
 
 
 
 
 
 47 
 
 
 
CHAPTER 3 
 RESEARCH METHODOLOGY 
 
3.1         INTRODUCTION 
 
This study adopted a quantitative, descriptive, and contextual research design 
insofar as the researcher was interested in analysing available and quantifiable 
data. The data employed were collected using a checklist covering 300 HIV-
positive patients’ records from one hospital in Ethiopia.    
 
3.2          STUDY DESIGN  
 
A research design is a written plan for a study (Kumar 2008:28). This design 
expresses a researcher’s intentions, the study’s purpose, and its value.  It also 
includes a step by step plan for the study’s implementation. A research design 
should be a logical and systematic plan that has been prepared in order that a 
research study is properly conducted. It is comparable to a blueprint that an 
architect prepares before construction of a building commences (Kumar 
2008:33). 
 
This study adopted attempted to analyse available and quantifiable data. This 
study is descriptive in nature insofar as the researcher will observe a situation 
(the referral of HIV-positive patients for TB screening) and then describe what 
has been observed (Donald et al 2010:27).  The description included is related to 
TB diagnosis amongst HIV-positive patients from one hospital in Ethiopia. This 
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study represents a formal, objective, systematic, and quantifiable process aimed 
at describing a specific situation (Burns & Grove 2005:44). The situation in 
question constitutes a review of the records of registered HIV-positive patients, 
done in order to identify whether or not TB screening was done in accordance 
with Ethiopia’s TB/HIV collaborative guidelines. Statistical analysis will be also 
used to summarise and describe the data collected. The aim of this study is to 
identify problems in the implementation of TB case detection amongst HIV-
positive patients from one hospital in Ethiopia using a structured checklist to 
analyse the available data records. 
   
3.2.1  Descriptive research 
 
This study was descriptive in nature because the researcher observed a situation 
and then described what had been observed (Babbie & Mouton 2001:80-81).  
The description in question is related to rates of TB screening amongst PLWHIV 
at one hospital in Ethiopia.   
        
3.2.2 Quantitative research 
 
This study was also a formal, objective, systematic, and quantitative process 
used to describe a particular situation (Burns & Grove 2005:44). The situation 
under analysis was a review of patients’ files applied in order to study rates of TB 
case detection among PLWHIV in the participating hospital. Statistics were used 
to summarise and describe the data. 
         
3.2.3 Contextual research 
 
A context is the complex of factors, conditions, and contradictory elements that 
either support or limit a historically and culturally related framework that is 
constantly changing (Eisner & Day 2008:440). For a contextual study, a case can 
be a person, an institution, a culture or a group. In this study the case was one 
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hospital where data had been recorded and analysed related to the records of 
HIV patients.   
        
 
3.3 RESEARCH METHOD  
  
This section covers the exact steps followed during the process of data 
collection.  These included definitions of the research population and of the 
research setting. 
    
3.3.1 Research population   
 
A research population is the set of elements on which a study focuses (Bless & 
Higson 2005:85). The population of research sites for this study comprised all the 
Ethiopian hospitals and all relevant clinics providing HIV/TB collaborative 
services to HIV positive patients. 
 
3.3.1.1 Site target population 
 
Only one HIV clinic of a single hospital in Adama, Ethiopia participated in this 
study.  This clinic has been offering TB/HIV collaborative services since 2002, 
and was purposively selected because it offers services to about 3 000 follow-up 
and 100 new PLWHIV per month.  
 
3.3.1.2 Accessible site 
 
This study was conducted at one HIV clinic in one public hospital in Ethiopia. The 
researcher conducted the study at this hospital’s clinic because it was one of the 
first nine public health facilities where TB/HIV collaborative management was 
piloted during 2002 (FMoH & FHAPCO 2007c:1).  As a result, this site offers an 
accessible opportunity from which to determine the extent to which TB/HIV 
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collaborative activities have been implemented over the ten years of this 
programme’s implementation.  The clinic attends to approximately 3 000 follow-
up and 100 newly diagnosed HIV patients per month. 
3.3.1.3 Target population  
 
The records of all patients who visited the targeted HIV clinic, at the participating 
hospital in Adama, comprised the accessible population for this study. The 
records of all 3 000 patients who visited the participating HIV clinic during the 
month of data collection (December 2012) comprised the target population for 
this study, provided that they were at least 18 years old (given the focus of the 
study on TB diagnosis and treatment among adult HIV-positive patients) and had 
been diagnosed as HIV-positive at least six months previously.  HIV patients 
attending the clinic who had been diagnosed less than six months prior to the 
data collection procedure were excluded from the study.  This limitation was 
applied because allowing six months since the patient’s HIV-positive diagnosis 
ensures sufficient time for the patient to have been referred for TB screening and 
to have collected some records about his or her TB diagnosis, treatment or 
prophylaxis. Including newly diagnosed HIV positive patients’ files might have 
produced some amount of contradictory variables because there could have 
been insufficient time for these patients’ TB treatment to have been properly 
recommended or implemented. 
 
3.3.1.4 Site sampling technique 
 
The participating hospital contains only one HIV clinic that participated in this 
study. This clinic was intentionally selected because it offers services to more 
than 3 000 follow-up and 100 new patients per month and has 10 years’ 
experience implementing TB/HIV collaborative programme. Questions of site 
sample size are not applicable since only one clinic participated in this study. 
 
3.3.2 Sampling  
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Random sampling was used until data from 300 HIV-positive patients (amounting 
to 10% of the total number of patients treated per month at the participating  
 
clinic) had been recorded, and a checklist related to every patient’s file had been 
completed. 
 
3.3.2.1 Sampling frame 
 
The HIV clinic’s register, which indicated the names and numbers of all patients 
who visited the HIV clinic during the data collection month in December 2012 
comprised the sampling frame for the population for this study. 
 
3.3.2.2 Sampling technique 
 
Random sampling was used to select the records of HIV-positive patients visiting 
the participating clinic during December 2012, until 300 follow-up patients’ files 
had been examined. A total of 15 files that met the inclusion criteria were 
selected on a daily basis. Every day the numbers of all files belonging to patients 
who visited the clinic on the day in question were written on slips of paper and 
placed into a container.  An independent person was asked to draw 15 numbers 
blindly from the container.  These 15 files were acquired and checked.  If any 
patient was younger than 18, or had been diagnosed as being HIV positive less 
than six months prior to the date of data collection, these files were excluded 
from the sample and additional numbers were drawn blindly from the container 
until 15 files had been selected for the day. 
 
3.3.3 Sample size 
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A total of 300 patients’ files was used, which amounted to 10% of the total 
population of follow-up HIV patients who visited the participating HIV clinic on a 
monthly basis. 
  
    
 
3.4 DATA COLLECTION 
 
3.4.1 The research instrument   
 
Checklists are defined by Burns & Grove (2005:791) as “Techniques for 
indicating whether a behavior occurred”. The major advantage of using a 
checklist was that the researcher had a structured approach to recording relevant 
data from a specific patient’s file to his/her checklist, by ticking off the relevant 
recorded behaviours.  A potential disadvantage of using a checklist was that the 
researcher could miss important information not recorded on the checklist.  The 
researcher attempted to overcome this limitation by noting any information 
relevant to this study, but not covered in the checklist, as notes on the checklist. 
 
A checklist was designed by the researcher based on findings from an in-depth 
literature review, and the FMoH’s (2006) guidelines.  Health care workers’ 
expected behaviours to diagnose TB among HIV-positive persons were listed 
and the researcher could tick the behaviours recorded in the patients’ files.  The 
checklist was pre-tested on 10 HIV patients’ files that were excluded from the 
data analysis.  No amendments were required as a result of the checklist. The 
checklist was divided into the following three sections: 
 
Section A covered the patient’s biographic data, such as his or her gender, age, 
education, address, and marital status.   
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Section B collected information about the patient’s TB screening and diagnosis, 
such as when TB screening was conducted, method of TB screening used and 
the outcome of the TB screening.  
 
Section C investigated possible challenges and limitations related to TB/HIV 
collaborative activities in the hospital such as evidence of stigma, any reasons for 
late screening, contact tracing and HIV and TB treatment regimens.   
 
3.4.2 Data collection procedures  
 
While pre-testing the checklist, the researcher checked if all items on the 
checklist were relevant to the information recorded in the HIV patients’ files. No 
amendments were required as every item on the checklist was relevant to 
Ethiopia’s TB/HIV collaboration guidelines. The researcher numerically assigned 
a number to each checklist (ranging from 001 to 300) before data collection 
began.  The researcher kept a list indicating the checklist number and the 
corresponding patient’s HIV file number.  Only the researcher had access to this 
list, the hard copy of which was kept in a locked-up location and the MS Excel 
version of which was protected by a secure password on a computer to which 
only the researcher had access.  This enabled the researcher to retrace any 
specific patient’s HIV file should this have been required for research or oversight 
and review purposes.  This list will be destroyed after the current research report 
has been accepted.  
 
The following information was transcribed from the HIV registers onto each of the 
300 checklists:  
 
• Demographic profiles  
• Was the HIV positive patient screened for TB? 
• Was the HIV patient referred from the HIV clinic to a TB clinic for 
effective treatment? 
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• When was the first TB screening conducted? 
• What tests were used for TB screening? 
• Which category of healthcare professional performed the TB 
screening? 
• Which category of healthcare professional made a TB or non-TB 
diagnosis? 
• Did the patient receive INH prophylaxis, if not, why not, and if so, what 
was the outcome? 
 
In addition, any opportunistic infections (OIs) that the patient might have suffered 
from during the preceding six months were noted.   
    
3.4.3  Data analysis  
 
Data in this study were analysed using SPSS version 19 and Microsoft Excel. 
The analysis comprised descriptive statistics (frequency tables and graphs, p-
values, and correlations (Pearson rho) to summarise and describe data.  The 
researcher entered the data in the SPSS statistical software, and a statistician 
checked the data entries from the completed checklists and assisted the 
researcher in calculating and interpreting any relevant statistics. (Please see a 
letter from the statistician to this effect- Annexure F). 
  
3.5 VALIDITY  
      
Validity refers to the degree to which evidence and theory support the 
interpretations of test scores or those arguments entailed by proposed users of 
tests (Donald et al 2010:225).  
 
3.5.1 Internal validity 
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A study has internal validity to the degree that it concludes that a relationship 
between variables is causal or that the absence of the relationship implies a lack 
of cause (Ellen & Robert 2011:4).  In this study, the researcher measured 
independent and dependent variables to identify possible factors impacting on 
TB case detection among PLWHIV and further analysed the effect of delayed or 
absent TB screening.  
 
3.5.2 External validity 
 
A study has external validity to the degree that the results can be generalised 
beyond the current study to situations that use other methods, measures, and 
populations (Ellen & Robert 2011:5). This study was only conducted at one clinic, 
and the results cannot be generalised beyond this clinic, unless the study could 
be repeated at randomly selected HIV clinics across Ethiopia. 
 
The research instrument and checklist’s validity was tested based on face 
validity, content validity, and construct validity. The instrument was shared with 
experts working in the field of collaborative TB/HIV services to confirm its face 
validity.  The content validity of the checklist was evaluated by confirming that 
every item on the checklist was directly relevant to TB/HIV collaborative 
activities. The checklist’s construct validity was confirmed because the expert 
reviewers agreed that every item on the checklist related to the FMoH guidelines 
on TB/HIV collaborative activities. 
 
3.6     RELIABILITY 
 
Reliability refers to the degree to which a measure would produce the same 
results on different occasions (David 2010:28).  In other words, reliability is a 
matter of consistency of results obtained from using the same instrument on 
different occasions. 
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The data collected for this study can be verified by comparing the checklists’ 
information with that from the specific patient’s files. The research instrument 
was pre-tested on 10 HIV patients’ files that were subsequently excluded from 
participation in the actual study. The data for the 10 files were analysed before 
the data collection commenced to identify potential data entry and analysis 
problems. No such problems were encountered. 
 
3.7 ETHICAL CONSIDERATIONS   
 
Self-designed checklists were completed by the researcher, reflecting the data 
recorded in the selected patients’ files. No patient’s name and no healthcare 
worker’s name have been mentioned. Neither the participating HIV clinic’s name, 
nor the hospital’s name, has been mentioned in any report. No information was 
gathered from patients. 
 
Ethical clearance was granted by the Higher Degrees Committee of the 
Department of Health Studies, University of South Africa and by the manager of 
the hospital that participated in the study (see Annexures B and C). 
 
3.8      SUMMARY 
 
This study adopted a quantitative, descriptive, and contextual research design 
because the researcher was interested in analysing quantifiable data, available 
from HIV-positive patients’ files, pertaining to their TB screening, diagnoses, 
treatment and treatment outcomes.  
 
Data collection was conducted during December 2012 using a checklist to collect 
information from 300 randomly selected HIV-positive patients’ file. The collected 
data were analysed using the SPSS and MS Excel programs.   
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Chapter 4 presents an analysis and discussion of the data obtained as a result of 
the study outlined in this chapter.   
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CHAPTER 4 
ANALYSIS AND DISCUSSION OF RESEARCH RESULTS 
 
4.1         INTRODUCTION 
 
This chapter presents and discusses the results of the study. The overall goal of 
this study was to identify possible problems encountered during the 
implementation of TB case detection among HIV-positive patients at one hospital 
in Ethiopia. Based on this study’s findings, recommendations will be suggested 
for the improvement of existing TB/HIV management guidelines, the 
improvement of TB diagnosis of HIV-positive patients, and increasing the number 
of HIV-positive patients referred for effective TB treatment at the participating 
clinic. 
 
This study’s particular objectives were to: 
• Identify problems with the implementation of the TB/HIV guidelines at one 
hospital in Ethiopia 
• Assess whether the TB case detection among  HIV-positive persons was 
conducted according to the TB/HIV management guidelines 
• Identify which diagnostic procedures were used to detect TB among HIV- 
positive patients 
• Identify how long after a HIV-positive diagnosis a patient was referred for 
TB diagnostic tests 
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4.2          DATA MANAGEMENT AND ANALYSES  
 
The data collection instrument was organised into three sections: 
 
Section A: Biographic data 
Section B: TB tracing among HIV-positive persons at one participating HIV clinic 
Section C: Challenges and limitations related to TB/HIV collaboration activities at 
the participating hospital 
 
The data recorded on the checklists from the HIV-positive patients’ files, were 
analysed using SPSS version 17 and MS Excel programs. To see the 
relationship between two pieces of numerical data, such as a patient’s age and 
his/her CD4 count, a Pearson correlation coefficient was calculated with its 
corresponding p-value.  
 
In statistical significance testing the p-value is the probability of obtaining test 
result with statistics at least as extreme as the one that was actually observed, 
assuming that the null hypothesis is true. This implies no correlation existed 
between the relevant variables. The decision to “reject the null hypothesis” is 
taken when the p-value is less than the predetermined significance level which is 
often 0.05, indicating that the observed result would be highly unlikely. The p-
value ranges between +1 and -1.  “Probability statements are tested statistically 
to determine the extent of probability that B will occur in the event of A” (Burns & 
Grove 2001:138). Many common statistical tests, such as chi-square tests or the 
student’s t-test, produce statistics which can be interpreted using p-values. 
 
Pearson's correlation coefficient [r] is a measure of the strength and direction of 
the linear relationship between two variables that is defined in terms of the 
covariance of the variables divided by their standard deviations, giving a value 
between +1 and −1.  The correlation is strong if |r| >0.8, middle if 0.5 < |r| < 0.8, 
and weak otherwise.  
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 As a total of 300 patients’ records were reviewed, the total number of 
respondents will be indicated by N=300, any subtotals will be indicated by n and 
frequencies within subtotals will be indicated by f. 
 
4.3 DEMOGRAPHIC INFORMATION 
 
This section presents demographic data, followed by clinical data with 
discussions about TB case detection and TB/HIV co-management at the 
participating clinic. All figures are rounded off to the first decimal place. The 
demographic section addresses the results pertaining to the participants’ gender, 
ages, residential types, education levels and marital status. 
 
4.3.1 Gender 
 
A total of 300 HIV-positive patients’ records were analysed. Of the respondents 
56.2% (n=168) were females. In this study there were more females (56.2%; 
n=168) than males (43.8%; n=132) which reflects the higher HIV prevalence 
among females normally seen in the urban areas of Ethiopia. Reportedly the 
adult HIV prevalence rate in urban areas of Ethiopia is higher among females, 
9.25% compared to males (6.2%) (FMoH and FHAPCO 2007b:07). In a study 
conducted in Taiwan among 1 622 respondents, females were less likely to use a 
condom at their last sexual encounter which increased their chances of acquiring 
HIV infection (Tony et al 2011: 763). Gender and HIV risk have been widely 
examined in southern Africa, generally with a focus on dynamics within sexual 
relationships. “Yet the social construction of women’s lives reflects their broader 
engagement within a gendered social system, which influences both individual-
level risks and social and economic vulnerabilities to HIV/AIDS” (Abigail et al 
2013:1).   
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Figure 4.1: Respondents’ gender (n=300) 
 
4.3.2 Age 
 
In terms of the respondents’ age groups, 42.3% (n=127) were 31 to 40 years of 
age, followed by those aged 18 to 30 (26.3%; n=79), then those aged 41 to 50 
(23.7%; n=71), and those older than 50 (7.7%; n=23).  
 
The measures of central tendency of the respondents’ ages included a mean of 
36.47, median of 35.5 and standard deviation of 9.42. These statistics indicate 
that the average age of all respondents was 36.37 (mean) and that 50% of the 
respondents were younger and 50% were older than 35.5 (median) years of age. 
Besides, the average deviation of each respondent’s age from the mean age is 
9.42 which indicates there is variation, implying that 68.0% of all respondents’ ages 
varied between 45.79 (36.37 + 9.42) and 26.95 (36.37 – 9.42), as explained by 
Polit & Hungler (1991:416). This finding is consistent with the demographic health 
survey conducted in Ethiopia in 2012. For women HIV prevalence increases with 
age to a peak of 3.7% at age 30-34. For men, HIV prevalence increases from 0.0% 
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at age 15-19 to 3.0% at age 35-39 and drops thereafter. Overall, HIV prevalence is 
higher for women than men in most age groups ((Abigail et al 2013:1; CSA and 
Macro International 2012:256).  
 
 
 
Figure 4.2: Respondents’ age groups (N=300) 
 
 
4.3.3 Urban-rural residential areas 
 
Most respondents lived in urban environments (76.3%; n=229) and this could be 
attributable to the study site which was an HIV clinic at an urban hospital. Only 
16.0% of Ethiopia’s population lives in urban areas (CSA and Macro International 
2012:25). This finding is also supported by the single prevalence estimate 
conducted in Ethiopia in 2007. According to the FMoH and FHAPCO (2007:4) the 
rural component of the national HIV prevalence estimate for 2007 was 0.9% as 
rural prevalence and 7.7% for urban prevalence. 
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4.3.4 Marital status 
 
The marital status distribution shows that of the respondents 50.7% (n=152) were 
married, followed by those who were divorced or separated 19.3% (n=58), widowed 
16.3 % (n=49) and single 13.7% (n=41). This is also more or less similar with 
previous researchers’ reports. According to CSA and Macro International (2012:81) 
27% of women aged 15-49 were never married, 58% were married, 4% were living 
together with a man, and 11% were divorced, separated, or widowed. The low 
proportion (less than 1%) of women, aged 45-49, who had never been married 
indicates that marriage is nearly universal in this part of Ethiopia. 
 
A study conducted in Malawi, reported an association between marriage and HIV 
infection.  Although early sexual debuts, not marrying one’s first sexual partner and 
having a disrupted marriage increased the likelihood of HIV infection, their risk was 
not cumulative. Women who both delayed sexual debuts and did not marry their 
first sexual partners were more likely to experience marital disruption and to be 
HIV-positive than those who did not delay their sexual debuts but who married their 
first sexual partners (Boileau et al 2009:1). 
 
4.3.5 Education 
 
As far as their level of education was concerned, respondents who had not 
completed primary school made up 20.7% (n=62) of the total number, while 
37.3% (n=112) had completed primary school, 31.3% (n=94) had completed 
secondary school, and 10.7% (n=32) had completed some (unspecified) post-
school education. According to this study there was no evidence that a person’s 
educational level affected his/her TB case detection status. Whether a person 
had been educated or not, he/she could go through TB case detection as 
prescribed by the healthcare provider. This is also supported by a study 
conducted in Bangladesh (Mohammed et al 2002:1). This anonymous survey 
was conducted to assess the HIV-AIDS-related knowledge, practices and 
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behaviours of the respondents. Despite their low educational level, the 
respondents had a satisfactory level (93.4%) of essential knowledge about 
HIV/AIDS.  
 
Table 4.1: Respondents’ biographic information (N=300) 
 
Biographic Information Number  Percentage 
Gender 
   Male 
   Female 
 
132 
168 
 
44.0 
56.0 
Total 300 100.0 
Age group(mean=36.37,SD=9.42, md=35.5 ) 
   18 – 30 
31 – 40 
41 – 50 
>50 
 
79 
127 
71 
23 
 
26.3 
42.3 
23.7 
7.7 
Total 300 100.0 
Address 
   Urban 
   Rural 
 
229 
71 
 
76.3 
23.7 
Total 300 100.0 
Marital status 
   Single 
   Married 
   Divorced/separated 
   Widowed 
 
41 
152 
58 
49 
 
13.7 
50.7 
19.3 
16.3 
Total 300 100.0 
Educational status 
   Didn’t complete primary 
   Completed primary 
   Completed secondary 
   Post school qualification 
62 
112 
94 
32 
20.7 
37.3 
31.3 
10.7 
Total 300 100.0 
 
 
4.4 TB screening procedures followed by the HIV clinic 
 
Table 4.2 indicates that 99.3% (n=298) of the HIV-patients, had TB screening 
tests performed on the same day of enrolment at their respective HIV clinics. 
(“Enrolment” refers to the registration of the patients at the HIV clinic after their 
HIV diagnosis had been confirmed). According to Ethiopia’s TB/HIV 
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GUIDELINES (FMoH 2007:23) all HIV-positive patients should be screened by 
the HIV clinic, which was not fully implemented by the HIV clinic.  
 
This finding is also consistent with other research conducted in Ethiopia. 
According to Assefa (2011:411), intensified TB case finding is used in PLWHIV to 
reduce the burden of TB. A retrospective study was conducted among 300 
PLWHIVs attending an HIV clinic in Ethiopia to assess TB screening 
performance during a 12-month period. Between 80% and 95% of patients were 
screened for TB at enrolment and at each three monthly follow-up visit. Thirty-
four (11%) patients were diagnosed with TB.  
 
According to the WHO (2011:65), until 2010 data on intensified tracing for TB 
among people living with HIV and provision of IPT to those without active TB 
were requested from NTPs as part of the global TB data collection form. It was 
noted that monitoring of access to these two interventions at country level is 
considered weaker than for other interventions such as ART.  
 
According to the Ethiopian TB/HIV GUIDELINES, regular TB screening among 
HIV-positive patients, at every stage of the disease, is mandatory (FMoH 
2008:25), with the aim to reduce the burden of TB among PLWHIV. 
 
4.4.1 Methods used for TB screening  
 
According to the current study’s findings only clinical assessments were used for 
TB screening. These clinical assessments involved only a questionnaire of TB 
symptoms to be completed by the patient.  No laboratory tests were conducted.  
 
The WHO guidelines recommend TB screening using four symptoms (current 
cough, fever, weight loss and night sweats) and providing IPT if these symptoms 
are absent. This symptom-based screening questionnaire is effective in 
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accelerating TB screening in settings where the prevalence of TB among people 
living with HIV is 5% or higher (WHO 2011:68). 
 
In Ethiopia routine data from 44 sites in the year 2005/6 showed that 41% of TB 
patients were HIV-positive.  Other routine data collected in 2006/7 showed that 
the co-infection rate was 31% (FMoH 2007:9). Therefore, rigorous TB tracing 
mechanisms are suggested by the national TB/HIV Guideline.  Rates of smear-
negative pulmonary and extra pulmonary tuberculosis have been rising in 
countries experiencing HIV epidemics. The mortality rate among HIV-infected TB 
patients is higher than that of non-HIV infected TB patients, particularly for those 
with smear-negative PTB and extra EPTB. Delayed diagnosis might contribute to 
mortality among people living with HIV who have smear-negative PTB and EPTB 
(FMoH 2007:5).   These statistics necessitated the FMoH to insist on intensified 
TB case finding, including laboratory tests. For WHO stage 1 and 2 HIV-positive 
patients, the FMoH suggested clinical screening with sputum examinations. For 
HIV patients in WHO stage 3 and 4 it is highly recommended to conduct clinical 
assessments, sputum examinations, chest X-rays and other laboratory tests to 
increase the TB case detection rate (FMoH 2007:6).  The findings of this study 
did not indicate that the FMoH’s guidelines were fully implemented at the HIV 
clinic participating in this survey. 
 
There is growing evidence from national Ethiopian TB prevalence surveys and 
other research of a large pool of undetected TB in the community. Intensified 
efforts to further break down access barriers and scale up new and rapid 
diagnostic tools are likely to improve the situation particularly for high risk groups 
such as patients suffering from TB/HIV co-infection (Lonnroth 2013:289). 
 
TB case detection among HIV patients are categorised according to smear 
positive PTB, smear negative PTB and EPTB. In resource constraint and HIV 
highly prevalent settings, the WHO recommends conducting clinical symptom 
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assessments, AFB for sputum, sputum cultures or chest X-rays individualised 
according to the type of the TB (WHO 2007:6a).  
 
4.4.2 Outcomes of TB screening 
 
The goal of TB case detection among PLWHIV is to detect TB as early as 
possible and provide treatment or prophylaxis to PLWHIV to reduce morbidity 
and mortality. Intensified efforts are needed to approach the Global Plan’s targets 
of providing screening for TB for all those enrolled in HIV care and providing IPT 
to all those attending HIV care services who are eligible for it by 2015 (WHO 
2011:65). 
 
In this research, the outcomes of the TB screening procedures conducted 
amongst HIV patients included that: 
• 84.3% (n=253) had no TB 
• 11.7% (n=35) were TB suspect, and 
• 4.0% (n=12) were diagnosed as suffering from TB. 
 
Out of the 253 patients who did not have TB, 60.9% (n=154) started IPT. Out of 
these 154 IPT patients, 98.1% (n=151) completed their treatments, 1.3% (n=2) 
were on treatment, and 1.3% (n=2) defaulted before completing their IPT.  
Similar results were reported by a study conducted in Uganda. According to 
Namuwenge PM, et al (2011:1), a retrospective cohort study was conducted from 
2006-2008 and revealed that out of 586 patients who started IPT, 341 (58.2%) 
were lost to follow-up, 197 (33.6%) completed IPT, 29 (4.9%) discontinued IPT 
and 19 (3.2%) died. 
 
According to the WHO (2009c:12), IPT is effective among people living with HIV 
because it reduces the risk of developing active TB. The incidence of TB also 
decreases in HIV-positive cohorts on ART.  
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Therefore, increasing TB screening and enrolling eligible patients on IPT is a 
critical intervention for reducing morbidity and mortality of HIV patients. The 
finding of this research is also in line with findings from other countries as 
reported by the WHO. Globally, during 2008, almost 1.4 million TB patients were 
tested for HIV and accessed HIV prevention, treatment and care services, up 
from 1.2 million in 2007 (WHO 2009e:1). Of the TB patients who were known to 
be HIV-positive, two thirds (200 000) received co-trimoxazole treatment (CPT) 
and one third (100 000) received ART. During 2008, the number of people living 
with HIV, who were screened for TB, more than doubled from 600 000 in 2007 to 
1.4 million in 2008.  However, this represents only a fraction of the 33 million 
people estimated to be living with HIV. In 2008, only 56 000 people living with 
HIV, commenced IPT but TB infection control measures are not yet implemented 
in many HIV service settings, particularly in the SSA region.  All these figures are 
powerful indicators for a need of accelerated implementation of TB/HIV 
collaborative activities, particularly TB case detection among PLWHIV, (WHO 
2009e:2) to reduce the mortality and morbidity rates among persons co-infected 
with TB and HIV. 
 
Furthermore the FMoH insists that strict IPT adherence should be encouraged 
among all IPT patients.  However, TB must be excluded before IPT can be 
commenced even in areas where diagnostic capacities are limited. In settings 
where there are no facilities for chest x-rays, it might be better not to start IPT for 
symptomatic patients as they might indeed be suffering from TB.   It would be 
advisable to do TB evaluations on WHO stage 3 and 4 HIV patients three months 
after commencing ART, so as to decide whether to implement IPT or not (FMoH 
2007:16). 
 
The implementation of IPT intervention has been a challenge at the global level. 
IPT has been shown to be beneficial for PLWHIV, but uptake has been slow due 
to resource constraints and reluctance on the part of policy makers and 
programme implementers. IPT is primarily an HIV intervention, which should be  
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the responsibility of national AIDS programmes, HIV services, and primary health 
care (PHC) services where PLWHIV receive treatment. Prevention of TB in this 
population will contribute to the overall goal of reducing the global TB burden and 
improving the quality of life of PLWHIV (Getahun 2010:57).  
 
Out of 300 HIV-positive patients, 15.3 % (n=46) were diagnosed with TB. Out of 
these 46 TB patients, 34.8% (n=16) were diagnosed with smear positive PTB, 
34.8% (n=16) with smear negative PTB, and 30.4% (n=14) with EPTB. The 
TB/HIV GUIDELINES is in line with the global WHO recommendations in terms 
of diagnosing TB patients at the TB Clinic (WHO 2007:29; FMoH 2007:12). 
According to the WHO (2007:29) major changes in diagnosing TB patients 
among PLWHIV have been recommended:  
 
• the diagnosis should be adapted with patients suspected of having TB and 
living in settings with an HIV prevalence >1% among pregnant women or 
an HIV-prevalence ≥5% among TB patients  
• separate diagnostic guidelines should be followed for patient’s aged >15 
and for childhood TB (not applicable to this study which focussed only on 
adult TB patients) 
• adhering to the international standards for tuberculosis care 
• “trial” antibiotics is not required to diagnose smear-negative PTB 
• two sputum specimens, one must be collected in the morning, are 
sufficient for the initial diagnosis of TB in HIV patients  
• a patient is considered to have smear-positive TB if at least one sputum 
specimen is positive for AFB  
• sputum culture for MTB should be performed in patients who are sputum 
smear-negative to confirm the diagnosis of tuberculosis 
 
Out of the 38 respndents who were treated for TB, 86.8% (n=33) completed 
their treatment, 7.9% (n=3) were successfully cured, and 5.3% (n=2) were still 
on treatment. 
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Table 4.2 TB tracing among HIV-positive persons in the HIV clinic 
Background characteristics Number  Percentage 
TB screening tests performed 
   Same day 
   Missing 
 
298 
   2 
 
99.3 
  0.7 
Total 300 100.0 
TB screening method used 
   Clinical assessment 
   Other   
 
300 
    0 
 
100.0 
   0.0 
Total 300 100.0 
Outcome of TB screening 
   TB excluded 
   TB suspect 
   TB diagnosed    
 
253 
 35 
 12 
 
84.3 
11.7 
4.0 
Total 300 100.0 
IPT started for TB excluded 
   Yes 
   No 
 
154 
102 
 
  60.2 
  39.8 
Total 256 100.0 
Outcome of IPT 
   Still on treatment 
   Completed 
   Defaulted 
 
2 
151 
2 
 
1.3 
97.4 
1.3 
Total 155 100.0 
Type of TB diagnosed 
   Smear positive pulmonary TB 
   Smear negative pulmonary TB 
   Extra pulmonary TB 
 
16 
16 
14 
 
34.8 
34.8 
30.4 
Total 46 100.0 
Outcome of TB treatment 
   Still on treatment 
   Successfully treated 
   Successfully cured 
 
2 
33 
3 
 
    5.3 
   86.8 
    7.9 
Total 38 100.0 
 
According to Hannock (2013:1), out of 2 361 new smear-positive pulmonary TB 
patients, 86% had successful treatment outcome (were cured or completed 
treatment), 5% died, 6% were lost to follow-up, 1% failed treatment, and 2% 
transferred-out. A TB patient is considered to be cured if the patient who was 
initially smear-positive becomes smear-negative during the last month of 
treatment and on at least one previous occasion (WHO 2011:41). A patient will 
be considered as having completed TB treatment when he/she has completed 
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treatment but did not meet the criteria for cure or treatment failure. This definition 
applies to pulmonary smear-positive and smear-negative patients and to patients 
with EPTB. 
 
4.5 Challenges and limitations of TB-related activities at the hospital 
 
According to the FMoH (2007:22) TB case finding should be intensified in all HIV 
testing and counselling services for HIV-positive clients to identify TB suspects 
early before their condition deteriorates.  HIV-positive clients should be informed 
by the health care providers of HIV counselling and testing services about the 
advantages of being screened for TB.  Once informed about the risk of 
developing active TB, they should undergo screening for TB and they should be 
further evaluated, using the WHO algorithm, for improving the diagnosis of smear 
negative TB in HIV-positive patients. 
 
As shown in table 4.3, for 98.3% (n=295) of the patients, initial TB screening was 
conducted by a hospital nurse, followed by a hospital doctor (1.0%; n=3), or 
community health worker (0.7%; n=2). Only one patient’s file indicated that 
stigma was a challenge that caused the patient to refuse TB screening or IPT. 
Only one patient’s contacts were traced and found to be suffering from TB. Two 
patients were restarted on anti-TB category two drugs and their cultures and drug 
sensitivities were retested.  This was done because these two HIV-positive 
patients had developed TB re-infections although they had already received anti-
TB treatment. 
 
However, some studies on TB/HIV conducted in Ethiopia revealed significant 
double stigma of TB/HIV co-management. A study conducted in the Ormiya 
region, Ethiopia, had a total of 591 participants of whom 124 (21.0%) were co-
infected with TB/HIV. The stigma items were highly reliable (Cronbach's alpha = 
0.93) and had strong inter-dimensional correlations. Respondents who were co-
infected with TB and HIV were more likely to have perceived stigma compared to 
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non-co-infected HIV patients (OR=1.4, 95% CI). Non-literate individuals (OR = 
1.9, 95% CI) and females (OR = 1.6, 95% CI) reported more perceived stigma. 
 
Another study conducted in Addis Ababa, Ethiopia, indicated that stigma and 
knowledge about TB/HIV co-infection was limited. According to Mekdes et al 
(2011:1) a qualitative study was conducted among 12 TB/HIV patients and 9 
health workers. Most patients were aware of an association between TB and 
HIV. Some reported that TB could transform into HIV, while others said that the 
body could be weakened by HIV and become more susceptible to illnesses such 
as TB. Some patients classified TB as either HIV-related or non-HIV-related, and 
weight loss was a hallmark for HIV-related TB. Most patients believed that people 
in the community knew that there was an association between TB and HIV, and 
some feared that this would predispose them to HIV-related stigma. 
 
 Table 4.3 Challenges and limitations of TB-related activities  
Background characteristics Number Percentage 
Health professional who conducted TB screening  
   Community health worker 
   Hospital nurse 
   Hospital Doctor    
 
   2 
295 
   3 
 
  0.7 
 98.3 
   1.0 
Total 300 100.0 
Stigma as a challenge for TB screening and 
preventive therapies  
   Yes 
   No    
 
 
   1 
294 
 
 
  0.3 
 99.7 
Total 295 100.0 
Able to trace TB patient’s contact 
   Yes 
   No       
 
   1 
252 
 
  0.4 
 99.6 
Total 253 100.0 
Contacts tested positive for TB 
   Yes 
   No 
 
   1 
294 
 
  0.3 
  99.7 
Total 295 100.0 
What done for re-infection of TB 
   Culture and drug sensitivity test 
       Yes 
        No 
 
 
2 
298 
 
 
0.7 
99.3 
Total 300 100 
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   Referral to MDR centre  
       Yes 
        No 
 
1 
299 
 
0.3 
99.7 
Total 300 100 
Restarting the patient on category two of anti TB 
drugs  
       Yes 
        No 
 
 
2 
298 
 
 
0.7 
99.3 
Total 300 100 
 
4.6 Clinical Findings 
The clinical findings of this study, discussed in the following sections, include 
CD4 counts’ correlations with HAART and TB/HIV co-management. 
 
4.6.1 CD4 counts and relationships with HAART 
 
According to Williams et al. 2013:2798, the concentration of CD4 T-lymphocytes 
(CD4 count), in a person's plasma is widely used to decide when to start HIV-
positive people on ART and to predict the impact of ART on the future course of 
HIV and TB. However, CD4 cell counts vary widely within and among populations 
and depend on many factors besides HIV-infection. The way in which CD4 counts 
decline over the course of HIV infection is neither well understood nor widely 
agreed upon. 
 
In this study, in terms of patients’ CD4 count at the point of the start of their HAART 
treatment, 72.1 %( n=214) were under 200, 23.2% (n=69) within the range of 200-
349, and 4.7% (n=14) had CD4 counts greater than or equal to 350.  
 
The measures of central tendency of the respondents’ CD4 counts during a 
time in which HAART had been started included a mean of 172.34, median of 
124.5 and standard deviation of 80.86. These statistics indicate that the 
average CD4 count of all respondents was 172.34 (mean) and that 50% of the 
respondents had CD4 counts of less than 124.5 while 50% of respondents have 
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greater than 124.5 CD4 count (median). Besides, the average deviation of each 
respondent’s CD4 count from the mean CD4 count was 80.86, indicating 
variations, implying that 46.92% of all respondents’ CD4 count varied between 
253.2 (172.34 + 80.86) and 91.48 (172.34 – 80.86). 
 
The Pearson correlation coefficient between patients’ CD4 count for the duration 
of their HAART and their age was calculated to be r=-0.041 with a p-value of 
0.485. This depicts a slightly negative correlation as the age of the patient 
increased, the CD4 count decreased, and vice versa. This relationship, however, 
was not statistically significant at the 5% level, since the p-value of 0.43 is 
greater than 0. This finding of this study is also supported by another study 
conducted in Nepal in 2012. Bhatta et al (2012:6) conducted a descriptive 
retrospective cross-sectional study among 258 clients, at registered  ART sites in 
the Doti district from August to October 2011. There was significant improvement 
in CD4 counts in patients taking ART within the first year of treatment and yet the 
mortality rate among this group was also high in these six months.  This finding 
indicates that the first six months of ART is crucial for every aspect of 
management of the HIV-positive patients.  
 
4.6.2 TB/HIV co management  
 
According to the WHO (2008d:1), TB is the most frequent life threatening 
opportunistic disease for PLWHIV, even in those receiving ARVs. TB remains 
the leading cause of death. Thus, TB/HIV co-management is a key intervention 
to improve the quality of life of PLWHIV.   
 
The Ethiopian ART Guidelines (FMoH 2006: 24) indicate that all TB patients at 
WHO clinical stage III with CD4 counts < 350 cells/mm3 are eligible for ART. TB 
patients with WHO clinical stage IV defining conditions are also eligible for ART, 
irrespective of their CD4 count.  
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Table 4.4 indicates that 95.7% (n=287) of the patients’ CD4 counts were used as 
indicators to start HAART, while for 60% (n=180) clinical assessments were also 
employed. For only one patient the viral load was used as an indicator to start 
HAART. 
 
According to Salim et al (2010:543) an open-label, randomised, controlled trial in 
Durban, South Africa, was conducted among 642 patients with both TB and HIV 
infection to start antiretroviral therapy either during anti-TB therapy (in two 
integrated therapy groups) or after the completion of such treatment (in one 
sequential therapy group). The initiation of ART during anti-TB therapy 
significantly improved survival and provided further impetus for the integration of 
TB and HIV services.  
 
Another study in Ethiopia has revealed the importance of TB/HIV co- 
management. According to Sileshi et al (203:297), despite the availability of free 
ART from health institutions in Northwest Ethiopia, mortality was high among TB-
HIV co-infected patients, and strongly associated with the absence of ART during 
TB treatment. In addition prophylactic therapy remained an important factor in the 
reduction of mortality rates during anti-TB treatment. The study also noted the 
importance of early commencement of ART even at higher CD4 counts. Another 
study also indicated simultaneous HAART and TB treatment in dual infected 
patients to be associated with improved survival rates (Velasco et al 2009:148).  
 
According to the WHO (2009b:71), when TB is diagnosed in patients already 
receiving ART, TB treatment should be started immediately. There are two 
issues to consider in such cases.  Firstly it must be established whether ART 
needs to be modified because of drug–drug interactions or to reduce the 
potential for overlapping toxicities, since both treatments can be hepato-toxic.  
Secondly it needs to be determined whether the presentation of active TB in a 
patient on ART constitutes ART failure that requires a change in the ART 
regimen. 
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According to the FMoH (2007:17), the first line HAART regimen comprises 
Stavudine, Lamuvidine, and Nevirapine. But Stavudine is associated with major 
potential toxicity, neuropathy, pancreatitis and lipo-atrophy while Nevirapine is 
related with hepatotoxicity and severe rashes. If Nevirapine is used with 
Rifampicin and INH, severe hepato-toxicity is a potential side effect. Thus for 
TB/HIV co-infected patients it is suggested to use an Efavirenz-based regimen.  
 
In addition, according to Dianna et al (2004:1), 49 AIDS patients, most of whom 
were on ART, with active TB, were treated with Rifampin 600mg, Isoniazid 
400mg and Pirazinamide 2g daily. They also received ARVs, consisting of 
Efavirenz (600mg/day) plus 2 NRTIs. All patients were prospectively followed up 
for at least 24 months.  A non-concomitant ARV regimen was introduced at least 
three weeks after TB treatment initiation. Severe adverse reactions included 
rashes (two), toxic hepatitis (six), IRIS (seven), and four deaths. The study 
concluded that Efavirenz at a daily dose of 600 mg was sufficient and safe to 
treat TB/HIV patients using a rifampicin-containing regimen.   
 
In the current study, the proportions of the total number of treatment regimens 
used for existing HIV-positive patients on treatment were:- 
• Stavudine (d4T) + Lamivudine (3TC) + Nevirapine (NVP), 33.3% (n=82) 
• Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP), 19.9% (n=49),    
• Zidovudine (AZT) + Lamivudine (3TC) + Efavirenz(EFV), 2.8%(n=7), and 
• Other regimens 43.9% (n=108). 
 
The proportions of the total number of treatment regimens used for the new HIV-
positive patients, in the current study, on treatment were:- 
• Stavudine (d4T) + Lamivudine (3TC) + Nevirapine (NVP), 5.1% (n=2),  
• Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP), 5.1% (n=2),    
• Zidovudine (AZT) + Lamivudine (3TC) + Efavirenz(EFV), 17.9% (n=7), and 
• Other regimen, 71.8% (n=28). 
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These figures indicate that for all of the patients with newly commenced HAART 
treatment regimes, Nevirapine-based regimens were excluded. This is a good 
practice for TB/HIV co-infected patients, as they would not be forced to change 
their HAART regimen when they start their anti-TB treatment.  
 
According to the WHO (2007:62), the use of INH, the main anti-TB drug used 
with a HAART regimen containing Nevirapine, increases heap-totoxicity. Some of 
the critical decisions in the management of TB/HIV co-infected patients include 
when to start ART (tarting); when to substitute one therapy for another because 
of significant side effect (ubstitution); when to switch therapy because of 
treatment failure (witching); and when to stop therapy and move to end-of life and 
palliative care due to second-line regimen treatment failure (topping) (FMoH 
2007:9) 
 
 
 
Table 4.4 Challenges and limitations of HIV-related activities in the hospital 
 
 
Background characteristics Number Percentage 
Indicators used to start HAART 
   CD4 count 
       Yes 
        No 
 
287 
 13 
 
 95.7 
   4.3 
Total 300 100.0 
   Viral load 
       Yes 
        No 
 
   1 
299 
 
  0.3 
 99.7 
Total 300 100.0 
   Clinical assessment 
       Yes 
        No 
 
180 
120 
 
60.0 
 40.0 
Total 300 100.0 
CD4 count while HAART started 
(mean=172.34, st.devn.=80.86, median=124.5) 
   < 200 
   200 – 349 
   >= 350 
 
214 
  69 
  14 
 
 72.1 
 23.2 
   4.7 
Total 297 100.0 
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Treatment regimen for new HIV-positive patient 
   Stavudine (d4T) + Lamivudine (3TC) + Nevirapine (NVP)   
   Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP) 
   Zidovudine (AZT) + Lamivudine (3TC) + Efavirenz(EFV) 
   Other regimen 
 
  82 
  49 
    7 
108 
 
 33.3 
19.19 
    2.8 
 43.9 
Total 246 100.0 
Treatment regimen for the existing HIV patient on 
treatment 
   Stavudine (d4T) + Lamivudine (3TC) + Nevirapine (NVP)   
   Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP) 
   Zidovudine (AZT) + Lamivudine (3TC) + Efavirenz(EFV) 
   Other regimen 
 
 
  2 
  2 
  7 
28 
 
 
  5.1 
   5.1 
 17.9 
 71.8 
Total 39 100.0 
 
 
4.7 CONCLUSION  
 
According to this study individual’ gender and age group were found to be 
statistically significant predictors for starting IPT among TB-excluded HIV-positive 
patients. 
 
The findings of this study depicted that for the 99.3% of the HIV-positive patients 
TB screening was performed on the same day of enrolment at their respective 
HIV clinics. And the percentage of the outcome of TB screening for HIV patients 
were 84.3% for TB-excluded followed by 11.7% TB-suspects and 4% TB- 
diagnosed. 
 
The next chapter will present the conclusions, limitations and recommendations 
of this study as well as propose areas for possible future research.
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CHAPTER 5 
 CONCLUSIONS, LIMITATIONS AND 
RECOMMENDATIONS 
 
5.1 INTRODUCTION 
 
The purpose of the study was to identify problems encountered during the 
implementation of TB case detection among HIV-positive persons at one hospital 
in Ethiopia. The time and type of TB diagnostic procedures were examined. 
Based on the findings of this study, recommendations are suggested to improve 
the existing TB/HIV co-management guidelines to improve the TB diagnosis of 
HIV-positive persons, and to increase the number of HIV-positive patients 
referred for effective TB treatment at the participating site. 
 
This chapter presents the conclusions of the study which are related to the 
following research questions stated in section 1.4 of this dissertation: 
• What percentage of HIV-positive persons were screened for TB in the HIV 
clinic based on the reports in the patients’ files? 
• How long after the diagnosis of being HIV-positive, was the patient 
referred for TB screening? 
• What treatment was provided to the HIV-positive persons diagnosed with 
TB? 
• What were the TB treatment outcomes of the referred HIV-positive 
persons? 
 
This chapters also identified the limitations of the study and provides possible 
recommendations which are relevant for conducting future studies and for 
enhancing the TB/HIV co-management strategies at the participating hospital in 
Ethiopia. 
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5.2   CONCLUSIONS IN RELATION TO THE STUDY’S OBJECTIVES 
 
The purpose of the study was to identify problems encountered during the 
implementation of TB case detection among HIV-positive persons at one hospital 
in Ethiopia. 
 
5.2.1 Objective: Identify problems with the implementation of the TB/HIV 
guidelines at one hospital in Ethiopia 
 
Out of the 256 patients for whom TB had been excluded, 60.2% (n=154) had 
started IPT. All these 256 patients should have commenced with IPT to prevent 
the progression of latent TB to active TB, and to help prevent further 
transmission of TB in the communities. IPT is the one of the key intervention to 
reduce morbidity and mortality among TB/HIV clients.  
 
5.2.2 Objective: Assess whether the TB case detection among HIV-positive 
persons are conducted according to the TB/HIV management guidelines. 
 
As shown in table 4.3, most patients’ initial TB screening tests were conducted 
by hospital nurses (98.3%) compared to the 1.0% done by hospital doctors. The 
NTG states this screening should be done by qualified health professionals.  
Quality TB/HIV care is required to suppress the HIV to an undetectable level and 
cure TB to increase immunological responses and enhance patients’ well-being.  
Qualified and trained health workers improved the quality of patients’ lives 
through decreasing morbidity of these two diseases (WHO 2004a:1; WHO 
2012:83).  
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5.2.3 Objective: Identify what diagnostic procedures were used to detect TB 
among HIV-positive persons  
 
In this study it was revealed that HIV-positive patients’ CD4 counts were not 
considered when they were screened for TB by completing questionnaires.  No 
laboratory tests were performed. This traditional symptom screening is 
insufficient for detecting TB disease among HIV infected persons particularly for 
HIV patients at advanced WHO stages.  In addition to the questionnaire, x-rays 
and sputum examinations could enhance the early diagnosis and timely 
treatment of TB. It will also prevent giving INH prophylaxis to HIV-positive 
patients who might be suffering from TB but who remained undetected when the 
questionnaires were completed. 
5.2.4 Objective: Identify how long after being diagnosed HIV-positive, a 
patient was referred for TB investigations 
The results show, for the 99.3% of the respondents, TB screening test was 
performed on the same day of enrolment at their respective HIV clinics. This is in 
line with the WHO recommendation which states that TB screening should be 
done at the time that HIV infection is diagnosed, before the initiation of ART and 
at regular intervals during follow up. 
 
Implications: All TB screening is conducted on the same day of their visit to HIV 
clinic which is in line with the national TB/HIV Guideline. However, all possible 
efforts should be made to screen all 100% of HIV patients visiting the clinic 
(WHO 2012:83).  
 
5.3 LIMITATIONS OF THE STUDY 
 
The limitations that were identified during the study included that: 
• The study was conducted at one of the nine Ethiopian public health 
facilities where the TB/HIV collaborative management had been piloted 
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since 2005 which cannot be generalised to the whole country’s TB/HIV 
collaborative activities. 
• A review of the HIV-positive patients’ records was done. No information 
was collected from health professionals about the actual performance of 
their HIV/TB collaborative activities in the hospital that participated in this 
study. 
• This research covered only 10% of the estimated population of 3 000 
follow-up HIV patients who are visiting this clinic on a monthly basis. 
• It is a quantitative study which was not supported by qualitative data.   
 
5.4    RECOMMENDATIONS 
 
The following recommendations could help to improve TB case detections 
among HIV-postivie patients at one hospital in Ethiopia: 
• The hospital should be equipped to test HIV-positive patients for TB by 
using chest x-rays, sputum smears and microscopic cultures and 
sensitivity examinations. 
• If IPT is administered to HIV-positive patients suffering from TB, INH 
resistance could develop. Therefore it is necessary to design improved 
ways of delivering IPT especially to those with early HIV infection, for 
whom TB has definitely been excluded. 
• Because of the poor performance of sputum smear microscopy in HIV 
infected patients, newer diagnostic tests are urgently required that are not 
only sensitive and specific but also easy to use in remote and resource 
constrained settings. 
 
The following recommendations pertain to future studies assisting researchers to 
increase the quality and coverage of TB case identification: 
• Similar studies duplicated in other health facilities would enable  
comparisons of the findings and possible generalisations to more facilities  
providing HIB/TB collaborative services. 
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• The association should be investigated between the status of HIV-
positive TB-excluded patients who commenced IPT early and completed 
the prophylactic regimen, and patients who did not do so. 
• Reasons should be investigated as to why only patients’ completed 
questionnaires were accepted as clinical assessments of TB screening.  
The possibility of using x-rays and laboratory tests should also be 
investigated as well as the cost-effectiveness of this potential approach. 
Meticulous records should be kept of all HIV-positive patients who were 
diagnosed with TB at any stage. 
• The effectiveness of TB screening conducted mostly by hospital nurses 
should be investigated, potential shortcomings identified and addressed 
by in-service education and sustained audits of patients’ records. 
• Problems encountered by the health professionals at public health 
facilities to apply the country’s guidelines for TB/HIV co-infected patients 
should be investigated on an ongoing basis and remedial actions should 
be implemented. 
• Conduct qualitative research to determine the knowledge, attitudes and 
perceptions of people in the community concerning the association 
between HIV and TB. 
• Monitor the quality of TB screening methods used at the participating 
hospital and other public health facilities where TB/HIV collaborative 
activities are implemented. 
• Identify factors influencing the treatment of TB among HIV patients. 
 
Regular audits should be done to keep management informed about the 
challenges and the accomplishments experienced by health care workers during 
the implementation of the TB/HIV collaboration guidelines. 
 
Basic and post basic nursing, medical and related programmes should 
emphasise the dire necessity for implementing effective TB/HIV collaborative 
activities.  Regular in-service education sessions should also address this issue. 
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5.6  CONCLUDING  REMARKS 
 
Diagnosing TB among HIV-infected individuals is a major public health challenge. 
This study showed that screening for TB is based almost exclusively on 
questionnaires completed by patients to assess clinical symptoms. In the hospital 
chest x-rays, sputum smear and microscopic culture and sensitivity were not 
used as TB screening methods.  
 
The findings of this study revealed 99.3% of the HIV-positive patients had TB 
screening tests performed on the same day that they enrolled at their respective 
HIV clinics. The outcomes of TB screening for HIV-positive patients were:  84.3% 
for TB-excluded followed by 11.7% TB-suspected and 4% TB- diagnosed. 
 
Out of 300 HIV-positive patients, 46 (15.3%) were diagnosed as suffering from 
TB: 16 (34.8%) were smear positive PTB, 16 (34.8%) were smear negative PTB 
and 14(4.7%) were EPTB.  
  
Only one patient refused TB screening due to the fear of stigmatisation of TB in 
the community. 
 
Van Rie, Westreich and Sanne (2011:354) maintain that “… TB remains a major 
challenge to the health of people living with HIV in sub-Saharan Africa, even 
among those receiving ART.  Severity of HIV disease is the strongest risk factor 
for prevalent and early incident TB and response to ART the strongest risk factor 
for late incident TB. Early initiation of ART will significantly reduce TB incidence 
among people on ART…”  Thus it remains vital that TB should be diagnosed and 
treated early among HIV-positive patients, and that IPT should be administered 
early to prevent the development of TB in HIV-positive patients who do not suffer 
from TB.  However, IPT must be avoided in all persons already suffering from 
TB, explaining why accurate diagnosis of TB remains vital for commencing IPT or 
anti-treatment before complications arise. 
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=============================================================== 
Date: 08/14/ 2012  
 
 
To: Manager,  Adama  Hospital  
       Ethiopia, Adama 
 
 
                             Re: Support Letter  
 
I am called Dr Tedla Mezemir Damte who has worked as a clinician, medical director, 
health department head, university lecturer/health faculty dean, and public health 
implementer with international organizations and UN agencies at different level in health 
development field.  In regard with my professional development, I am doing my MPH 
degree with University of South Africa.  
 
As part of completion of my MPH degree, I am currently doing my thesis titled as 
‘Tuberculosis case detection among HIV positive persons in a hospital in Ethiopia’. As 
you might be aware I have worked in the same hospital for long time as a deputy director 
and director of this hospital. In addition, I led the establishment of the HIV clinic in the 
hospital. This would have given me a better understanding of the situation and therefore I 
would like to conduct my research in Adama Hospital.    
 
The aim of this study is to assess the implementation of TB case detection among HIV 
positive persons in Adama hospital.  
 
Specific objectives include;  
• Assess whether the TB case detection among  HIV positive persons are conducted 
according to the TB/HIV management guidelines 
• Identify how TB case detection among HIV positive persons was conducted (what 
diagnostic TB procedures were conducted)  
• Identify how long after the diagnosis of being HIV positive, a patient was referred 
for TB investigations. 
The finding of this study will be used as an input to strengthen the quality of the TB/HIV 
co management in Adama Hospital, Ethiopia. The research will also be used to enrich the 
body of knowledge and baseline references for TB/HIV in the country, which will 
support the scale up of the service in the country. The main finding of this study will be 
presented to relevant MoH structure such as Ethiopian Public Health Association.   
 
Thus, I am kindly asking your support to conduct the assessment in the in your Hospital, 
which is the referral hospital for this specific region of the country.  
 
 
Thank you in advance for the support, 
 
 
 
With many regards, 
 
 
Tedla Mezemir Damte 
Final Year UNISA Student 
Std No: 36670650 
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Annexure B:  Checklist (research instrument) 
 
TUBERCULOSIS CASE DETECTION AMONG HIV POSITIVE PERSONS IN A HOSPITAL 
IN ETHIOPIA  
INSTRUMENT: 
 
The researcher will complete a checklist from each patient’s file.  The 
researcher will keep a list indicating the checklist number and the 
corresponding patient’s HIV register number in an excel sheet format, 
but no patient’s file number will be entered onto any checklist. The 
researcher will also keep the file under lock and correlate every 
completed checklist’s number with the patient’s file number, in case 
future audits of the entered data might be required. 
 
CHECKLIST  
SECTION I: Biographic  data 
No Questions Coding categories Remark 
001 Checklist no  ............  
002 Gender   
1. Male 
2. Female 
 
003 Age of the patient  1. 18 – 29  
2. 30 – 39 
3. 40 -49 
4. 50 and older 
 
004 Permanent address of the patient  1. Urban   
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2. Rural 
005 Marital status of the patient 1. Single 
2. Co-habiting 
3. Married 
4. Divorced/Separated 
5. Widowed 
6. Not recorded 
 
006 Educational status of the patient 1. Did not complete primary 
school 
2. Completed primary school 
(7 years) 
3. Completed secondary 
school (12 years) 
4. Post school qualifications, 
please specify 
 
SECTION B: TB tracing among HIV positive persons  in the HIV clinic 
 No Questions Coding categories Remark 
007 After how many days of enrolment in the HIV 
clinic, was TB screening tests performed? 
  
1- Same day 
2-  2-29 days 
3- 30 – 89days 
4- 90 days or more 
 
008 How many times did the patient visit the HIV 
clinic before the first TB screening test was 
done? 
 ........times  
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009 What TB screening method was used?    
(mark every test done) 
1. Clinical assessment  
2. Chest x-rays 
3. Sputum smear 
4. Microscopic culture and 
sensitivity 
 
 
010 What was the outcome of the screening for 
the patient?  
1. TB excluded 
2. TB suspect 
3. TB diagnosed (please 
specify date of TB 
diagnosis) 
4. Not recorded  
 
011 If TB was excluded, did the patient start with 
IPT?   
1. Yes  
2. No 
 
012 If the patient was on IPT what was the 
outcome? 
1. Still on treatment 
2. Completed  
3. Defaulted 
 
013 If the patient defaulted on the IPT, what was 
the reason?  (Please record all relevant 
reasons). 
1. Patient refused treatment 
2. Side effects (please specify) 
3. Family influence (please 
specify) 
4. Physician’s decision (give a 
reason) 
5. Patient referred to other 
facility (give a reason) 
6. Patient discontinued clinic 
visits (since what date?) 
7. Not recorded 
 
014 On what date was the patient (diagnosed 
with TB) referred to the TB clinic?  
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015 Which type of TB was diagnosed? 1. Smear Positive Pulmonary TB 
2. Smear Negative Pulmonary TB 
3. Extra Pulmonary TB (please 
specify organs affected by TB) 
4. Others, please specify  
……………………………….. 
 
016 If the patient was treated for TB what was the 
outcome? 
1. Still on treatment 
2. Successfully treated 
(specify reason) 
3. Successfully cured (based 
on what clinical results?) 
4. Defaulted (after how many 
weeks on TB treatment?) 
5. Not recorded  
 
 
017 During the period when the patient was on 
anti TB & ART, what consequences were 
reported? 
1. Anti TB discontinued because 
of side effects 
2. ART discontinued because of 
side effects 
3. ART regimen changed due to 
side effect 
4. CD4 count deteriorated due to 
anti TB treatment  
5. Patient discontinued follow up 
6. Others, please specify 
 
SECTION C: Challenges and limitations about TB/HIV collaborative activities in the 
hospital 
 No Questions Coding categories Remark 
018 Which health professional category 
conducted the first TB screening? 
1. Community Health Worker 
2. Hospital Nurse 
3. Hospital Doctor 
4. Doctor at TB clinic 
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5. Others, Please specify 
6. TB screening form is not 
available in the patient’s file 
019 Is stigma recorded in the patient’s file as 
a challenge for refusing TB screening or 
for taking TB preventive therapies?  
1. Yes  
2. No  
 
020 If the HIV positive patient was screened 
for TB after 6 months after enrolment at 
the HIV clinic, what was/were the 
reason(s) for late screening? (more than 
one reason can be indicated) 
1. Lack of lab supplies 
2. Shortage of health personnel  
3. Lack of other diagnostic 
equipments 
4. Lack of drugs and commodities 
5. Fear of stigma and discrimination 
6. Omission by the health workers 
contacted the patient  
7. Patient refusal 
8.  Other, please specify 
 
21 Were the TB patient’s contacts traced?  1. Yes 
2. No  
 
22 If the answer to q21 is “yes” please 
specify what tests were done on these 
contacts 
 TB tests done on contacts: 
…………………………………………. 
…………………………………………. 
 
23 If contact tracing was done please 
indicate how many contacts of the patient 
were traced for each listed category 
1. Only partner/s (no….) 
2. Children (no… ) 
3. Other family members (no…) 
4. All close contacts who visited 
the patient during the previous 
month (no…..) 
  
 
24 If contacts were traced, how many 
contacts tested positive for TB? 
1. Yes 
2. No 
 
25 Please indicate which indications were 
used to start HAART? (More than answer 
can be recorded) 
1  CD4 count 
2  Viral load 
3  Clinical assessment 
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4   Not indicated   
26 Please indicate the CD4 count when 
HAART was started?  Please provide 
the exact CD4 count in every case and 
then circle the relevant category. 
1. Up to 199  
2. Between 200-349 
3. 350 or more 
4. Not recorded 
5. Exact CD 4 count when 
HAART was started……… 
 
27 If the HIV patient was on anti TB 
treatment and developed re-infection of 
TB, what has been done for the patient? 
1. Culture and drug sensitivity test 
2. Referral to MDR centre  
3. Restarting the patient on 
category two of anti TB drugs 
4. Others, please specify 
…………………………………… 
 
28 Which treatment regimen was used for 
the new HIV positive patient on treatment 
during August 2012? 
1. Stavudine (d4T) + Lamivudine 
(3TC) + Nevirapine (NVP)   
2. Zidovudine (AZT) + Lamivudine 
(3TC) + Nevirapine (NVP) 
3. Zidovudine (AZT) + Lamivudine 
(3TC) + Efavirenz(EFV) 
4. Other regimen please specify 
………………………………….  
 
29 Which treatment regimen was used for 
the existing HIV patient on treatment 
during August 2012? 
1. Stavudine (d4T) + Lamivudine 
(3TC) + Nevirapine (NVP)   
2. Zidovudine (AZT) + Lamivudine 
(3TC) + Nevirapine (NVP) 
3. Zidovudine (AZT) + Lamivudine 
(3TC) + Efavirenz(EFV) 
4. Other regimen, please specify 
...................................................... 
 
30 For how long did the  patient take his/her  
TB treatment? 
  -----months   
31 If the anti TB treatment was discontinued 
how many days after initiation of the TB 
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treatment was it discontinued?  
32 For patients on TB/HIV co-treatment, 
when was the side effect intolerable and 
prominent? 
1. During intensive phase (first 
two month) 
2. During continuation phase  
3. During full course of the anti TB 
treatment 
4. Not applicable 
 
33 If the patient received INH, what was the 
outcome of this treatment? 
  
34  If the patient received CPT, what was the 
outcomes of this treatment? 
  
35 List all infections which the patient had 
during the preceding six months 
  
36  For each infections listed in 35, please 
add the treatment provided and the 
outcome 
  
 
March 16, 2013 
 
Subject: Letter from Statistician 
 
My name is Girum Taye Zeleke, BSc. in Statistics and MSc.in the field of Epidemiology 
and Biostatistics, currently serving as a lecturer of statistics at Kigali Institute of Science 
and Technology (KIST), Rwanda. 
 
I have a tremendous experience in health related data analysis, presentation and 
interpretation.  
 
This is to notify that I have provided statistical analysis assistance to Dr. Tedla Mezemir 
Damte for his interesting M.Sc. dissertation entitled “Tuberculosis case detection among 
HIV-positive persons in a hospital in Ethiopia”  
 
 
With Best Regards 
 
Girum 
